# EDGAR Filing Document

**Accession Number:** 0001939965
**File Stem:** 0001213900-25-112142
**Filing Date:** 2025-11
**Character Count:** 199758
**Document Hash:** d235d21340ce95e0a512163687c73d07
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-112142.hdr.sgml**: 20251118

**ACCESSION NUMBER**: 0001213900-25-112142

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20251118

**FILED AS OF DATE**: 20251118

**DATE AS OF CHANGE**: 20251118

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Brera Holdings PLC
- **CENTRAL INDEX KEY:** 0001939965
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-AMUSEMENT & RECREATION SERVICES [7900]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L2
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41606
- **FILM NUMBER:** 251495287

**BUSINESS ADDRESS:**
- **STREET 1:** CONNAUGHT HOUSE, 5TH FLOOR
- **STREET 2:** ONE BURLINGTON ROAD
- **CITY:** DUBLIN 4
- **STATE:** L2
- **ZIP:** D04 C5Y6
- **BUSINESS PHONE:** 949-233-7869

**MAIL ADDRESS:**
- **STREET 1:** CONNAUGHT HOUSE, 5TH FLOOR
- **STREET 2:** ONE BURLINGTON ROAD
- **CITY:** DUBLIN 4
- **STATE:** L2
- **ZIP:** D04 C5Y6

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Brera Holdings Ltd
- **DATE OF NAME CHANGE:** 20220726

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER** 

**PURSUANT TO RULE 13a-16 OR 15d-16 OF THE** 

**SECURITIES EXCHANGE ACT OF 1934**

For the month of November 2025

Commission File Number 001-41606

**BRERA HOLDINGS PLC**

(Translation of registrant's name into English)

**Connaught House, 5th Floor**

**One Burlington Road**

**Dublin 4**

**D04 C5Y6**

**Ireland**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

**INCORPORATION BY REFERENCE**

This Report on Form 6-K shall be deemed to be incorporated by reference into the shelf registration statement on [Form F-3](http://www.sec.gov/Archives/edgar/data/1939965/000121390024010076/ea192704-f3_brerahold.htm) (Registration Number 333-276870) of Brera Holdings PLC, a public limited company incorporated in Ireland (the "Company"), filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") on February 5, 2024 and declared effective by the SEC on February 13, 2024 (the "Shelf Registration Statement"), and into each prospectus or prospectus supplement outstanding under the Shelf Registration Statement, to the extent not superseded by documents or reports subsequently filed or furnished by the Company under the Securities Act of 1933, as amended (the "Securities Act"), or the Securities Exchange Act of 1934, as amended.

**INFORMATION CONTAINED IN THIS FORM 6-K REPORT**

On November 18, 2025, the Company entered into a Controlled Equity Offering<sup>SM</sup> Sales Agreement (the "Sales Agreement") with Cantor Fitzgerald & Co. (the "Agent"), pursuant to which the Company, from time to time, at its option may offer and sell Class B ordinary shares, nominal value $0.05 per share (the "ATM Shares"), to or through the Agent, acting as principal and/or the sole sales agent, having an aggregate sales price of up to $98,500,000 (the "ATM Offering").

Subject to the terms and conditions of the Sales Agreement, the Agent will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the ATM Shares from time to time, based upon the Company's instructions. The Company has provided the Agent with customary indemnification and contribution rights in favor of the Agent, and the Agent will be entitled to a commission of 3.0% of the aggregate gross proceeds from each sale of the ATM Shares pursuant to the Sales Agreement.

Sales of the ATM Shares, if any, under the Sales Agreement may be made in transactions that are deemed to be "at the market offerings" as defined in Rule 415 under the Securities Act, or by any other method permitted by law. The Company has no obligation to sell any of the ATM Shares and may at any time suspend offers under the Sales Agreement or terminate the Sales Agreement.

This description of the Sales Agreement does not purport to be complete and is qualified in its entirety by reference to the Sales Agreement, which is attached hereto as Exhibit 1.1 and incorporated by reference herein.

The ATM Shares to be sold under the Sales Agreement, if any, will be issued and sold pursuant to the Shelf Registration Statement , including a base prospectus as part of the Shelf Registration Statement, and a prospectus supplement dated November 18, 2025 relating to the offer and sale of the ATM Shares pursuant to the Sales Agreement.

This Report on Form 6-K shall not constitute an offer to sell or a solicitation of an offer to buy any securities nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. The legal opinion of Clark Hill Solicitors LLP relating to the legality of the issuance and sale of the ATM Shares pursuant to the ATM Offering is attached as Exhibit 5.1 to this Report on Form 6-K and is incorporated herein by reference.

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 1.1 | [Controlled Equity Offering<sup>SM</sup> Sales Agreement, dated as of November 18, 2025, by and between the Company and Cantor Fitzgerald & Co.](ea026599401ex1-1_brera.htm) |
| 5.1 | [Opinion of Clark Hill Solicitors LLP](ea026599401ex5-1_brera.htm) |
| 23.1 | [Consent of Clark Hill Solicitors LLP (included in the opinion filed as Exhibit 5.1 hereto)](ea026599401ex5-1_brera.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  | **BRERA HOLDINGS PLC** | **BRERA HOLDINGS PLC** | **BRERA HOLDINGS PLC** |
| Date: November 18, 2025 | By: | /s/ Marco Santori | /s/ Marco Santori |
|  |  | Name: | Marco Santori |
|  |  | Title: | Chief Executive Officer |

---

## Exhibit 1.1

**Exhibit 1.1**

**Brera Holdings PLC**<br> Class B Ordinary Shares

($0.05 nominal value per share)

**Controlled Equity Offering<sup>SM</sup>**

**<u>Sales Agreement</u>**

November 18, 2025

Cantor Fitzgerald & Co.

110 East 59<sup>th</sup> Street

New York, NY 10022

Ladies and Gentlemen:

Brera Holdings PLC, a private company limited by shares incorporated under the laws of Ireland (the "**<u>Company</u>**"), confirms its agreement (this "**<u>Agreement</u>**") with Cantor Fitzgerald & Co. (the "**<u>Agent</u>**"), as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Issuance and Sale of Shares</u>. The Company agrees that, from time to time during the term of this
Agreement, on the terms and subject to the conditions set forth herein, it may issue and sell to or through the Agent, as principal and/or
sales agent, Class B ordinary shares (the "  **<u>Placement Shares</u>**") of the Company, $0.05 nominal value per share
(the "  **<u>Ordinary Shares</u>** "); *provided*, *however*, that in no event shall the Company issue or sell through
the Agent such number or dollar amount of Placement Shares that would (a) exceed the number or dollar amount of Ordinary Shares registered
on the effective Registration Statement (as defined below) pursuant to which the offering is being made, (b) exceed the number of authorized
but unissued Ordinary Shares (less Ordinary Shares issuable upon exercise, conversion or exchange of any outstanding securities of the
Company or otherwise reserved from the Company's authorized shares), (c) exceed the number or dollar amount of Ordinary Shares permitted
to be sold under Form F-3 (including General Instruction I.B.5 thereof, if applicable) or (d) exceed the number or dollar amount of Ordinary
Shares for which the Company has filed a Prospectus Supplement (as defined below) (the lesser of (a), (b), (c) and (d), the "  **<u>Maximum Amount</u>** "). Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitations
set forth in this <u>Section 1</u> on the amount of Placement Shares issued and sold under this Agreement shall be the sole responsibility
of the Company and that the Agent shall have no obligation in connection with such compliance. The offer and sale of Placement Shares
through the Agent will be effected pursuant to the Registration Statement (as defined below) filed by the Company and declared effective
by the Securities and Exchange Commission (the "  **<u>Commission</u>**") on February 13, 2024, although nothing in this
Agreement shall be construed as requiring the Company to use the Registration Statement to issue Ordinary Shares.

The Company has filed, in accordance with the provisions of the Securities Act of 1933, as amended (the "**<u>Securities Act</u>**"), and the rules and regulations thereunder (the "**<u>Securities Act Regulations</u>**"), with the Commission a registration statement on Form F-3 (File No. 333-276870), including a base prospectus, relating to certain securities, including the Placement Shares to be issued from time to time by the Company, and which incorporates by reference documents that the Company has filed or will file in accordance with the provisions of the Securities Exchange Act of 1934, as amended (the "**<u>Exchange Act</u>**"), and the rules and regulations thereunder. The Company has prepared a prospectus supplement to the base prospectus included as part of the registration statement, which prospectus supplement relates to the Placement Shares to be issued from time to time by the Company (the "**<u>Prospectus Supplement</u>**"). Except where the context otherwise requires, such registration statement, including all documents filed as part thereof or incorporated by reference therein, and including any information contained in a Prospectus (as defined below) subsequently filed with the Commission pursuant to Rule 424(b) under the Securities Act Regulations or deemed to be a part of such registration statement pursuant to Rule 430B of the Securities Act Regulations, and any one or more additional effective registration statements on Form F-3 from time to time that will contain a base prospectus and related prospectus or prospectus supplement, if applicable (which shall be a Prospectus Supplement), with respect to the Placement Shares, is herein called the "**<u>Registration Statement</u>**." The base prospectus or base prospectuses, including all documents incorporated therein by reference, included in the Registration Statement, as they may be supplemented, if necessary, by a Prospectus Supplement, in the form in which such prospectus or prospectuses and/or Prospectus Supplement have most recently been filed by the Company with the Commission pursuant to Rule 424(b) under the Securities Act Regulations, together with any then issued Issuer Free Writing Prospectus(es) (as defined below), is herein called the "**<u>Prospectus</u>**."

Any reference herein to the Registration Statement, any Prospectus Supplement, the Prospectus or any Issuer Free Writing Prospectus, and, in each case, any amendments and supplements thereto, shall be deemed to refer to and include the documents, if any, incorporated by reference therein (the "**<u>Incorporated Documents</u>**"), including, unless the context otherwise requires, the documents, if any, filed as exhibits to such Incorporated Documents. Any reference herein to the terms "amend," "amendment" or "supplement" with respect to the Registration Statement, any Prospectus Supplement, the Prospectus or any Issuer Free Writing Prospectus shall be deemed to refer to and include the filing of any document under the Exchange Act on or after the most-recent effective date of the Registration Statement, or the date of the Prospectus Supplement, Prospectus or such Issuer Free Writing Prospectus, as the case may be, and incorporated therein by reference. For purposes of this Agreement, all references to the Registration Statement, the Prospectus or to any amendment or supplement thereto shall be deemed to include the most recent copy filed with the Commission pursuant to its Electronic Data Gathering Analysis and Retrieval system, or if applicable, the Interactive Data Electronic Application system when used by the Commission (collectively, "**<u>EDGAR</u>**").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Placements</u>. Each time that the Company wishes to issue and sell Placement Shares hereunder (each,
a "  **<u>Placement</u>** "), it will notify the Agent by email notice (or other method mutually agreed to by the parties)
of the number of Placement Shares to be issued, the time period during which sales are requested to be made, any limitation on the number
of Placement Shares that may be sold in any one day and any minimum price below which sales may not be made (a "  **<u>Placement Notice</u>** "), the form of which is attached hereto as <u>Schedule 1</u>. The Placement Notice shall originate from any of the
individuals from the Company set forth on <u>Schedule 3</u> (with a copy to each of the other individuals from the Company listed on such
schedule), and shall be addressed to each of the individuals from the Agent set forth on <u>Schedule 3</u>, as such <u>Schedule 3</u> may be amended in writing from time to time. The Placement Notice shall be effective unless and until (i) the Agent declines to accept
the terms contained therein for any reason, in its sole discretion, (ii) the entire amount of the Placement Shares thereunder have
been sold, (iii) the Company suspends sales under or terminates the Placement Notice, which suspension or termination rights may
be exercised by the Company in its sole discretion, (iv) the Company issues a subsequent Placement Notice and explicitly indicates that
the parameters of the subsequent Placement Notice supersede those parameters contained in the earlier delivered Placement Notice or (v) this
Agreement has been terminated under the provisions of <u>Section 12</u>. The amount of any discount, commission or other compensation
to be paid by the Company to the Agent in connection with the sale of the Placement Shares shall be calculated in accordance with the
terms set forth in <u>Schedule 2</u>. It is expressly acknowledged and agreed that neither the Company nor the Agent will have any obligation
whatsoever with respect to a Placement or any Placement Shares unless and until the Company delivers a Placement Notice to the Agent and
the Agent does not decline such Placement Notice pursuant to the terms set forth above, and then only upon the terms specified therein
and herein. In the event of a conflict between the terms of this Agreement and the terms of a Placement Notice, the terms of the Placement
Notice will control (unless such Placement Notice is declined, suspended or otherwise terminated in accordance with the terms of this
Agreement).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Sale of Placement Shares by the Agent</u>. Subject to the provisions of <u>Section 5(a)</u>, the Agent,
for the period specified in the Placement Notice, will use its commercially reasonable efforts consistent with its normal trading and
sales practices and applicable state and federal laws, rules and regulations and the rules of the Nasdaq Capital Market (the "  **<u>Exchange</u>** "),
to sell the Placement Shares up to the amount specified in, and otherwise in accordance with the terms of, such Placement Notice. The
Agent will provide written confirmation to the Company no later than the opening of the Trading Day (as defined below) immediately following
the Trading Day on which it has made sales of Placement Shares hereunder setting forth the number of Placement Shares sold on such day,
the average price at which the Placement Shares were sold on such day, the compensation payable by the Company to the Agent pursuant to <u>Section 2</u> with respect to such sales, and the Net Proceeds (as defined below) payable to the Company, with an itemization of the
deductions made by the Agent (as set forth in <u>Section 5(b)</u>) from the gross proceeds that it receives from such sales. Subject to
the terms of the Placement Notice, the Agent may sell Placement Shares by any method permitted by law deemed to be an "at the market
offering" as defined in Rule 415(a)(4) of the Securities Act Regulations. "  **<u>Trading Day</u>**" means any
day on which Ordinary Shares are traded on the Exchange.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. <u>Suspension of Sales</u>. The Company or the Agent may, upon notice to the other party in writing (including
by email correspondence to each of the individuals of the other party set forth on <u>Schedule 3</u>, if receipt of such correspondence
is actually acknowledged by any of the individuals to whom the notice is sent, other than via auto-reply) or by telephone (confirmed immediately
by verifiable facsimile transmission or email correspondence to each of the individuals of the other party set forth on <u>Schedule 3</u>),
suspend any sale of Placement Shares (a "  **<u>Suspension</u>** "); *provided*, *however*, that such Suspension
shall not affect or impair any party's obligations with respect to any Placement Shares sold hereunder prior to the receipt of such
notice. While a Suspension is in effect any obligation under <u>Sections 7(l)</u>, <u>7(m)</u>, and <u>7(n)</u> with respect to the delivery
of certificates, opinions, or comfort letters to the Agent, shall be waived. Each of the parties agrees that no such notice under this <u>Section 4</u> shall be effective against any other party unless it is made to one of the individuals named on <u>Schedule 3</u> hereto,
as such Schedule may be amended from time to time. Notwithstanding any other provision of this Agreement, during any period in which the
Company is in possession of material non-public information, the Company and the Agent agree that (i) no sale of Placement Shares will
take place, (ii) the Company shall not request the sale of any Placement Shares, and (iii) the Agent shall not be obligated to sell or
offer to sell any Placement Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. <u>Sale and Delivery to the Agent; Settlement</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Sale of Placement Shares</u> *.* On the basis of
the representations and warranties herein contained and subject to the terms and conditions herein set forth, upon the Agent's
acceptance of the terms of a Placement Notice, and unless the sale of the Placement Shares described therein has been declined, suspended,
or otherwise terminated in accordance with the terms of this Agreement, the Agent, for the period specified in the Placement Notice,
will use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable law, rules and regulations
to sell such Placement Shares up to the amount specified, and otherwise in accordance with the terms of such Placement Notice. The Company
acknowledges and agrees that (i) there can be no assurance that the Agent will be successful in selling Placement Shares, (ii) the Agent
will incur no liability or obligation to the Company or any other person or entity if it does not sell Placement Shares for any reason
other than a failure by the Agent to use its commercially reasonable efforts consistent with its normal trading and sales practices and
applicable law, rules and regulations to sell such Placement Shares as required under this Agreement and (iii) the Agent shall be under
no obligation to purchase Placement Shares on a principal basis pursuant to this Agreement, except as otherwise agreed by the Agent and
the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Settlement of Placement Shares</u> *.* Unless otherwise specified in the applicable Placement
Notice, settlement for sales of Placement Shares will occur on the first (1st) Trading Day (or such other day as is industry practice
for regular-way trading) following the date on which such sales are made (each, a "  **<u>Settlement Date</u>** "). The Agent
shall notify the Company of each sale of Placement Shares no later than the opening of the Trading Day immediately following the Trading
Day on which it has made sales of Placement Shares hereunder. The amount of proceeds to be delivered to the Company on a Settlement Date
against receipt of the Placement Shares sold (the "  **<u>Net Proceeds</u>**") will be equal to the aggregate sales price
received by the Agent, after deduction for (i) the Agent's commission, discount or other compensation for such sales payable by
the Company pursuant to <u>Section 2</u> hereof, and (ii) any transaction fees imposed by any Governmental Authority (as defined below)
in respect of such sales.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Delivery of Placement Shares</u>. On or before each Settlement Date, the Company will, or will cause
its transfer agent to, electronically transfer the Placement Shares being sold by crediting the Agent's or its designee's
account (provided the Agent shall have given the Company written notice of such designee at least one Trading Day prior to the Settlement
Date) at The Depository Trust Company through its Deposit and Withdrawal at Custodian System or by such other means of delivery as may
be mutually agreed upon by the parties hereto which in all cases shall be freely tradable, transferable, registered shares in good deliverable
form. On each Settlement Date, the Agent will deliver the related Net Proceeds in same day funds to an account designated by the Company
on, or prior to, the Settlement Date. The Company agrees that if the Company, or its transfer agent (if applicable), defaults in its obligation
to deliver Placement Shares on a Settlement Date, the Company agrees that in addition to and in no way limiting the rights and obligations
set forth in <u>Section 10(a)</u> hereto, it will (i) hold the Agent harmless against any loss, claim, damage, or expense (including reasonable
legal fees and expenses), as incurred, arising out of or in connection with such default by the Company or its transfer agent (if applicable)
and (ii) pay to the Agent any commission, discount, or other compensation to which it would otherwise have been entitled absent such default.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Denominations; Registration</u> *.* Certificates for the Placement Shares, if any, shall be in
such denominations and registered in such names as the Agent may request in writing at least one full Business Day (as defined below)
before the applicable Settlement Date. The certificates for the Placement Shares, if any, will be made available by the Company for examination
and packaging by the Agent in The City of New York not later than noon (New York time) on the Business Day prior to the applicable
Settlement Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Limitations on Offering Size</u> *.* Under no circumstances shall the Company cause or request
the offer or sale of any Placement Shares if, after giving effect to the sale of such Placement Shares, the aggregate gross sales proceeds
of Placement Shares sold pursuant to this Agreement would exceed the lesser of (A) together with all sales of Placement Shares under
this Agreement, the Maximum Amount and (B) the amount authorized from time to time to be issued and sold under this Agreement by
the Company's board of directors, a duly authorized committee thereof or a duly authorized executive committee, and notified to
the Agent in writing. Under no circumstances shall the Company cause or request the offer or sale of any Placement Shares pursuant to
this Agreement at a price lower than the minimum price authorized from time to time by the Company's board of directors, a duly
authorized committee thereof or a duly authorized executive committee. Further, under no circumstances shall the Company cause or permit
the aggregate offering amount of Placement Shares sold pursuant to this Agreement to exceed the Maximum Amount.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. <u>Representations and Warranties of the Company</u>. Except
as disclosed in the Registration Statement and the Prospectus, the Company represents and warrants to, and agrees with the Agent that
as of the date of this Agreement and as of each Applicable Time (as defined below), unless such representation, warranty or agreement
specifies a different date or time:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Registration Statement and Prospectus</u>. The Company and the transactions contemplated by this Agreement
meet the requirements for and comply with the applicable conditions set forth in Form F-3 (including General Instructions I.A and I.B)
under the Securities Act. The Registration Statement has been or will be filed with the Commission and has been or will be declared or
deemed effective by the Commission under the Securities Act prior to the issuance of any Placement Notices by the Company. As of each
Applicable Time, the Registration Statement is effective. The Prospectus Supplement will name the Agent as the agent in the section entitled
"Plan of Distribution." The Company has not received, and has no notice of, any order of the Commission preventing or suspending
the use of the Registration Statement, or threatening or instituting proceedings for that purpose. The Registration Statement and the
offer and sale of Placement Shares as contemplated hereby meet the requirements of Rule 415 under the Securities Act and comply in
all material respects with said Rule. Any statutes, regulations, contracts or other documents that are required to be described in the
Registration Statement or the Prospectus or to be filed as exhibits to the Registration Statement have been so described or filed. Copies
of the Registration Statement, the Prospectus, and any such amendments or supplements and all documents incorporated by reference therein
that were filed with the Commission on or prior to the date of this Agreement have been delivered, or are available through EDGAR, to
the Agent and its counsel. The Company has not distributed and, prior to the later to occur of each Settlement Date and completion of
the distribution of the Placement Shares, will not distribute any offering material in connection with the offering or sale of the Placement
Shares other than the Registration Statement and the Prospectus and any Issuer Free Writing Prospectus to which the Agent has consented,
which consent will not be unreasonably withheld, conditioned or delayed, or that is required by applicable law or the listing maintenance
requirements of Nasdaq. The Ordinary Shares are registered pursuant to Section 12(b) of the Exchange Act and are currently listed on the
Exchange under the trading symbol "SLMT." The Company has taken no action designed to, or likely to have the effect of, terminating
the registration of the Ordinary Shares under the Exchange Act, delisting the Ordinary Shares from the Exchange, nor has the Company received
any notification that the Commission or the Exchange is contemplating terminating such registration or listing. To the Company's
knowledge, it is in compliance with all applicable listing requirements of the Exchange.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>No Misstatement or Omission</u>. The Registration Statement, when it became or becomes effective, and
the Prospectus, and any amendment or supplement thereto, on the date of such Prospectus or amendment or supplement, conformed and will
conform in all material respects with the requirements of the Securities Act. At each Settlement Date, the Registration Statement and
the Prospectus, as of such date, will conform in all material respects with the requirements of the Securities Act. The Registration Statement,
when it became or becomes effective, did not, and will not, contain an untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary to make the statements therein not misleading. The Prospectus and any amendment and supplement
thereto, on the date thereof and at each Applicable Time (as defined below), did not or will not include an untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. The documents incorporated by reference in the Prospectus or any Prospectus Supplement did not, and any
further documents filed and incorporated by reference therein will not, when filed with the Commission, contain an untrue statement of
a material fact or omit to state a material fact required to be stated in such document or necessary in order to make the statements in
such document, in the light of the circumstances under which they were made, not misleading. The foregoing shall not apply to statements
in, or omissions from, any such document made in reliance upon, and in conformity with, information furnished to the Company by the Agent
in writing specifically for use in the preparation thereof, it being understood and agreed that the only such information furnished by
the Agent to the Company consists of Agent Information (as defined below).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Conformity with the Securities Act and Exchange Act</u>. The Registration Statement, the Prospectus,
any Issuer Free Writing Prospectus or any amendment or supplement thereto, and the documents incorporated by reference in the Registration
Statement, the Prospectus or any amendment or supplement thereto, when such documents were or are filed with the Commission under the
Securities Act or the Exchange Act or became or become effective under the Securities Act, as the case may be, conformed or will conform
in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Financial Information</u>. The consolidated financial statements of the Company included or incorporated
by reference in the Registration Statement, the Prospectus and the Issuer Free Writing Prospectuses, if any, together with the related
notes and schedules, present fairly, in all material respects, the consolidated financial position of the Company and the Subsidiaries
(as defined below) as of the dates indicated and the consolidated results of operations, cash flows and changes in shareholders'
equity of the Company for the periods specified (subject, in the case of unaudited financial statements, to normal year-end audit adjustments
which are not expected to be material, either individually or in the aggregate) and have been prepared in compliance with the requirements
of the Securities Act and Exchange Act and in conformity with International Financial Reporting Standards ( ***"* IFRS *"***)
applied on a consistent basis during the periods involved; the other financial and statistical data with respect to the Company and the
Subsidiaries (as defined below) contained or incorporated by reference in the Registration Statement, the Prospectus and the Issuer Free
Writing Prospectuses, if any, are accurately and fairly presented and prepared on a basis consistent with the financial statements and
books and records of the Company; there are no financial statements (historical or pro forma) that are required to be included or incorporated
by reference in the Registration Statement, or the Prospectus that are not included or incorporated by reference as required; the Company
and the Subsidiaries (as defined below) do not have any material liabilities or obligations, direct or contingent (including any off-balance
sheet obligations), not described in the Registration Statement (excluding the exhibits thereto), and the Prospectus; and all disclosures
contained or incorporated by reference in the Registration Statement, the Prospectus and the Issuer Free Writing Prospectuses, if any,
regarding "non-IFRS financial measures" (correlating to "non-GAAP financial measures", as such term is defined
by the rules and regulations of the Commission) comply with Regulation G of the Exchange Act and Item 10 of Regulation S-K under the Securities
Act, to the extent applicable and in all material respects. The interactive data in eXtensible Business Reporting Language included or
incorporated by reference in the Registration Statement and the Prospectus fairly presents the information called for in all material
respects and has been prepared in accordance with the Commission's rules and guidelines applicable thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Conformity with EDGAR Filing</u>. The Prospectus delivered to the Agent for use in connection with
the sale of the Placement Shares pursuant to this Agreement will be identical to the versions of the Prospectus created to be transmitted
to the Commission for filing via EDGAR, except to the extent permitted by Regulation S-T.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Organization</u>. The Company and each of its Subsidiaries are duly organized, validly existing as
a corporation or other business entity, as applicable, and in good standing under the laws of their respective jurisdictions of organization.
The Company and each of its Subsidiaries are duly licensed or qualified as a foreign corporation for transaction of business and in good
standing under the laws of each other jurisdiction in which their respective ownership or lease of property or the conduct of their respective
businesses requires such license or qualification, and have all corporate power and authority necessary to own or hold their respective
properties and to conduct their respective businesses as described in the Registration Statement and the Prospectus, except where the
failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, have a material
adverse effect or would reasonably be expected to have a material adverse effect on or affecting the assets, business, operations, earnings,
properties, condition (financial or otherwise), prospects, shareholders equity or results of operations of the Company and the Subsidiaries
taken as a whole, or prevent or materially interfere with consummation of the transactions contemplated hereby (a "  **<u>Material Adverse Effect</u>** ").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <u>Subsidiaries</u>. The subsidiaries set forth on <u>Schedule 4</u> (collectively, the "  **<u>Subsidiaries</u>** "),
are the Company's only significant subsidiaries (as such term is defined in Rule 1-02 of Regulation S-X promulgated by the Commission).
Except as set forth in the Registration Statement and in the Prospectus, the Company owns, directly or indirectly, all of the equity interests
of the Subsidiaries free and clear of any lien, charge, security interest, encumbrance, right of first refusal or other restriction, and
all the equity interests of the Subsidiaries are validly issued and are fully paid, nonassessable and free of preemptive and similar rights.
No Subsidiary is currently prohibited, directly or indirectly, from paying any dividends to the Company, from making any other distribution
on such Subsidiary's capital stock, from repaying to the Company any loans or advances to such Subsidiary from the Company or from
transferring any of such Subsidiary's property or assets to the Company or any other Subsidiary of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <u>No Violation or Default</u>. Neither the Company nor any of its Subsidiaries is (i) in violation
of its memorandum and articles of association or similar organizational documents; (ii) in default, and no event has occurred that,
with notice or lapse of time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition
contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its
Subsidiaries is a party or by which the Company or any of its Subsidiaries is bound or to which any of the property or assets of the Company
or any of its Subsidiaries are subject; or (iii) in violation of any law or statute or any judgment, order, rule or regulation of
any Governmental Authority, except, in the case of each of clauses (ii) and (iii) above, for any such violation or default that would
not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. To the Company's knowledge, no
other party under any material contract or other agreement to which it or any of its Subsidiaries is a party is in default in any respect
thereunder where such default would have a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>No Material Adverse Change</u>. Subsequent to the respective dates as of which information is given
in the Registration Statement, the Prospectus and the Issuer Free Writing Prospectuses, if any (including any document deemed incorporated
by reference therein), there has not been (i) any Material Adverse Effect or the occurrence of any development that the Company reasonably
expects will result in a Material Adverse Effect, (ii) any transaction which is material to the Company and the Subsidiaries taken as
a whole, (iii) any obligation or liability, direct or contingent (including any off-balance sheet obligations), incurred by the Company
or any Subsidiary, which is material to the Company and the Subsidiaries taken as a whole, (iv) any material change in the capital stock
or outstanding long-term indebtedness of the Company or any of its Subsidiaries or (v) any dividend or distribution of any kind declared,
paid or made on the capital stock of the Company or any Subsidiary, other than in each case above in the ordinary course of business or
as otherwise disclosed in the Registration Statement or Prospectus (including any document deemed incorporated by reference therein).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) <u>Capitalization</u>. The issued and outstanding shares of capital stock of the Company have been validly
issued, are fully paid and nonassessable and, other than as disclosed in the Registration Statement or the Prospectus, are not subject
to any preemptive rights, rights of first refusal or similar rights. The Company has an authorized, issued and outstanding capitalization
as set forth in the Registration Statement and the Prospectus as of the dates referred to therein (other than the grant of additional
options under the Company's existing stock option plans, or changes in the number of outstanding Ordinary Shares of the Company
due to the issuance of shares upon the exercise or conversion of securities exercisable for, or convertible into, Ordinary Shares outstanding
on the date hereof) and such authorized capital stock conforms to the description thereof set forth in the Registration Statement and
the Prospectus. The description of the securities of the Company in the Registration Statement and the Prospectus is complete and accurate
in all material respects. Except as disclosed in or contemplated by the Registration Statement or the Prospectus, as of the date referred
to therein, the Company does not have outstanding any options to purchase, or any rights or warrants to subscribe for, or any securities
or obligations convertible into, or exchangeable for, or any contracts or commitments to issue or sell, any shares of capital stock or
other securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) <u>Authorization; Enforceability</u>. The Company has full legal right, power and authority to enter into
this Agreement and perform the transactions contemplated hereby. This Agreement has been duly authorized, executed and delivered by the
Company and is a legal, valid and binding agreement of the Company enforceable in accordance with its terms, except to the extent (i)
as limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors' rights generally, (ii) as
limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies or by general equitable
principles and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) <u>Authorization of Placement Shares</u>. The Placement Shares, when issued and delivered pursuant to
the terms approved by the board of directors of the Company or a duly authorized committee thereof, or a duly authorized executive committee,
against payment therefor as provided herein, will be duly and validly authorized and issued and fully paid and nonassessable, free and
clear of any pledge, lien, encumbrance, security interest or other claim, including any statutory or contractual preemptive rights, resale
rights, rights of first refusal or other similar rights, and will be registered pursuant to Section 12 of the Exchange Act. The Placement
Shares, when issued, will conform in all material respects to the description thereof set forth in or incorporated by reference into the
Prospectus.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) <u>No Consents Required</u>. No consent, approval, authorization, order, registration or qualification
of or with any Governmental Authority is required for the execution, delivery and performance by the Company of this Agreement, the issuance
and sale by the Company of the Placement Shares, except for (i) such consents, approvals, authorizations, orders and registrations or
qualifications as may be required under applicable state securities laws or by the by-laws and rules of the Financial Industry Regulatory
Authority ("  **<u>FINRA</u>**") or the Exchange (including any required notices) in connection with the sale of the Placement
Shares by the Agent and (ii) as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n) <u>No Preferential Rights</u>. Except as set forth in the Registration Statement and the Prospectus, (i) no
person, as such term is defined in Rule 1-02 of Regulation S-X promulgated under the Securities Act (each, a "  **<u>Person</u>** "),
has the right, contractual or otherwise, to cause the Company to issue or sell to such Person any Ordinary Shares or shares of any other
capital stock or other securities of the Company, (ii) no Person has any preemptive rights, resale rights, rights of first refusal,
rights of co-sale, or any other rights (whether pursuant to a "poison pill" provision or otherwise) to purchase any Ordinary
Shares or shares of any other capital stock or other securities of the Company, (iii) no Person has the right to act as an underwriter
or as a financial advisor to the Company in connection with the offer and sale of the Ordinary Shares, and (iv) other than disclosed
in the documents filed by the Company on EDGAR, no Person has the right, contractual or otherwise, to require the Company to register
under the Securities Act any Ordinary Shares or shares of any other capital stock or other securities of the Company, or to include any
such shares or other securities in the Registration Statement or the offering contemplated thereby, whether as a result of the filing
or effectiveness of the Registration Statement or the sale of the Placement Shares as contemplated thereby or otherwise (except for, in
the case of clauses (i) and (ii), such matters as would not, individually or in the aggregate, reasonably be expected to materially adversely
affect the ability of the Company to sell the Placement Shares).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o) <u>Independent Public Accounting Firm</u>. Reliant CPA PC ("  **<u>Reliant</u>**") and TAAD
LLP ("  **<u>TAAD</u>** ", together with Reliant, the "  **<u>Accountants</u>** "), whose respective reports on
the consolidated financial statements of the Company are filed with the Commission as part of the Company's most recent Annual Report
on Form 20-F filed with the Commission and incorporated by reference into the Registration Statement and the Prospectus, are and, during
the periods covered by their respective reports, were independent registered public accounting firms within the meaning of the Securities
Act and the Public Company Accounting Oversight Board (United States). To the Company's knowledge, the Accountants are not in violation
of the auditor independence requirements of the Sarbanes-Oxley Act of 2002 (the "  **<u>Sarbanes-Oxley Act</u>**") with respect
to the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p) <u>Enforceability of Agreements</u>. All agreements between the Company and third parties expressly referenced
in the Prospectus, other than such agreements that have expired by their terms or whose termination is disclosed in documents filed by
the Company on EDGAR, are legal, valid and binding obligations of the Company and, to the Company's knowledge, enforceable in accordance
with their respective terms, except to the extent that (i) enforceability may be limited by bankruptcy, insolvency, reorganization,
moratorium or similar laws affecting creditors' rights generally and by general equitable principles (ii) enforceability may be
limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) the
indemnification provisions of certain agreements may be limited by federal or state securities laws or public policy considerations in
respect thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q) <u>No Litigation</u>. Except as set forth in the Registration Statement or the Prospectus, there are no
actions, suits or proceedings by or before any Governmental Authority pending, nor, to the Company's knowledge, any audits or investigations
by or before any Governmental Authority to which the Company or a Subsidiary is a party or to which any property of the Company or any
of its Subsidiaries is the subject that, individually or in the aggregate, if determined adversely to the Company or any of its Subsidiaries,
would reasonably be expected to have a Material Adverse Effect and, to the Company's knowledge, no such actions, suits, proceedings,
audits or investigations are threatened or contemplated by any Governmental Authority or threatened by others; and (i) there are
no current or pending audits or investigations, actions, suits or proceedings by or before any Governmental Authority that are required
under the Securities Act to be described in the Prospectus that are not so described; and (ii) there are no contracts or other documents
that are required under the Securities Act to be filed as exhibits to the Registration Statement that are not so filed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(r) <u>Consents and Permits</u>. The Company and each Subsidiary possess such valid and current certificates,
authorizations or permits issued by the appropriate state, federal or foreign regulatory agencies or bodies necessary to conduct their
respective businesses, and neither the Company nor any Subsidiary has received, or has any reason to believe that it will receive, any
notice of proceedings relating to the revocation or modification of, or non-compliance with, any such certificate, authorization or permit
which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would, individually or in the aggregate,
reasonably be expected to result in a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(s) <u>Intellectual Property</u>. Except as disclosed in the Registration Statement and the Prospectus, the
Company and its Subsidiaries own, possess, license or have other rights to use all foreign and domestic patents, patent applications,
trade and service marks, trade and service mark registrations, trade names, copyrights, licenses, inventions, trade secrets, technology,
Internet domain names, know-how and other intellectual property (collectively, the "  **<u>Intellectual Property</u>** "),
necessary for the conduct of their respective businesses as now conducted except to the extent that the failure to own, possess, license
or otherwise hold adequate rights to use such Intellectual Property would not, individually or in the aggregate, have a Material Adverse
Effect. Except as disclosed in the Registration Statement and the Prospectus (i) there are no rights of third parties to any such Intellectual
Property owned by the Company and its Subsidiaries; (ii) to the Company's knowledge, there is no infringement by third parties of
any such Intellectual Property; (iii) there is no pending or, to the Company's knowledge, threatened action, suit, proceeding or
claim by others challenging the Company's and its Subsidiaries' rights in or to any such Intellectual Property, and the Company
is unaware of any facts which could form a reasonable basis for any such action, suit, proceeding or claim; (iv) there is no pending or,
to the Company's knowledge, threatened action, suit, proceeding or claim by others challenging the validity or scope of any such
Intellectual Property; (v) there is no pending or, to the Company's knowledge, threatened action, suit, proceeding or claim by others
that the Company and its Subsidiaries infringe or otherwise violate any patent, trademark, copyright, trade secret or other proprietary
rights of others; (vi) to the Company's knowledge, there is no third-party U.S. patent or published U.S. patent application which
contains claims for which an Interference Proceeding (as defined in 35 U.S.C. § 135) has been commenced against any patent or patent
application described in the Prospectus as being owned by or licensed to the Company; and (vii) the Company and its Subsidiaries have
complied with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or such Subsidiary,
and all such agreements are in full force and effect, except, in the case of any of clauses (i)-(vii) above, for any such infringement
by third parties or any such pending or threatened suit, action, proceeding or claim as would not, individually or in the aggregate, result
in a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(t) <u>Market Capitalization</u>. At the time the Registration Statement was or will be originally declared
effective, and at the time the Company's most recent Annual Report on Form 20-F was filed with the Commission, the Company met the
then applicable requirements for the use of Form F-3 under the Securities Act, including, but not limited to, General Instruction I.B.6
of Form F-3. The aggregate market value of the outstanding voting and non-voting common equity (as defined in Securities Act Rule
405) of the Company held by persons other than affiliates of the Company (pursuant to Securities Act Rule 144, those that directly, or
indirectly through one or more intermediaries, control, or are controlled by, or are under common control with, the Company) (the
"  **<u>Non-Affiliate Shares</u>** "), is greater than $1 billion (calculated by multiplying (x) the highest price
at which the common equity of the Company closed on the Exchange within 60 days of the date of this Agreement times (y) the number of
Non-Affiliate Shares). The Company is not a shell company (as defined in Rule 405 under the Securities Act) and has not been a shell company
for at least 12 calendar months previously and if it has been a shell company at any time previously, has filed current Form 10 information
(as defined in General Instruction I.B of Form F-3) with the Commission at least 12 calendar months previously reflecting its status as
an entity that is not a shell company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(u) <u>FINRA Matters</u>. The information provided to the Agent by the Company, its counsel, and its officers
and directors for purposes of the Agent's compliance with applicable FINRA rules in connection with the offering of the Shares is
true, complete, and correct and compliant with FINRA's rules in all material respects. The Company meets the definition of the term
"experienced issuer" specified in FINRA Rule 5110(j)(6).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) <u>No Material Defaults</u>. Neither the Company nor any of the Subsidiaries has defaulted on any installment
on indebtedness for borrowed money or on any rental on one or more long-term leases, which defaults, individually or in the aggregate,
would have a Material Adverse Effect. The Company has not filed a report pursuant to Section 13(a) or 15(d) of the Exchange Act since
the filing of its last Annual Report on Form 20-F, indicating that it (i) has failed to pay any dividend or sinking fund installment
on preferred stock or (ii) has defaulted on any installment on indebtedness for borrowed money or on any rental on one or more long-term
leases, which defaults, individually or in the aggregate, would have a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(w) <u>Certain Market Activities</u>. Neither the Company, nor any of the Subsidiaries, nor any of their respective
directors, officers or controlling persons has taken, directly or indirectly, any action designed, or that has constituted or would reasonably
be expected to cause or result in, under the Exchange Act or otherwise, the stabilization or manipulation of the price of any security
of the Company to facilitate the sale or resale of the Placement Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) <u>Broker/Dealer Relationships</u>. Neither the Company nor any of the Subsidiaries (i) is required
to register as a "broker" or "dealer" in accordance with the provisions of the Exchange Act or (ii) directly
or indirectly through one or more intermediaries, controls or is a "person associated with a member" or "associated
person of a member" (within the meaning set forth in the FINRA Manual).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(y) <u>No Reliance</u>. The Company has not relied upon the Agent or legal counsel for the Agent for any legal,
tax or accounting advice in connection with the offering and sale of the Placement Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(z) <u>Taxes</u>. The Company and each of its Subsidiaries have filed all federal, state, local and foreign
tax returns which have been required to be filed and paid all taxes shown thereon through the date hereof, to the extent that such taxes
have become due and are not being contested in good faith, except where the failure to so file or pay would not have a Material Adverse
Effect. Except as otherwise disclosed in or contemplated by the Registration Statement or the Prospectus, no tax deficiency has been determined
adversely to the Company or any of its Subsidiaries which has had, or would have, individually or in the aggregate, a Material Adverse
Effect. The Company has no knowledge of any federal, state or other governmental tax deficiency, penalty or assessment which has been
or might be asserted or threatened against it which would have a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(aa) <u>Title to Real and Personal Property</u>. Except as set forth in the Registration Statement or the Prospectus,
the Company and its Subsidiaries have good and marketable title in fee simple to all items of real property owned by them, and good and
valid title to all personal property described in the Registration Statement or Prospectus as being owned by them, in each case free and
clear of all liens, encumbrances and claims, except those matters that (i) do not materially interfere with the use made and proposed
to be made of such property by the Company and any of its Subsidiaries or (ii) would not, individually or in the aggregate, have a Material
Adverse Effect. Any real or personal property described in the Registration Statement or Prospectus as being leased by the Company and
any of its Subsidiaries is held by them under valid, existing and enforceable leases, except those that (A) do not materially interfere
with the use made or proposed to be made of such property by the Company or any of its Subsidiaries or (B) would not be reasonably expected,
individually or in the aggregate, to have a Material Adverse Effect. Each of the properties of the Company and its Subsidiaries complies
with all applicable codes, laws and regulations (including, without limitation, building and zoning codes, laws and regulations and laws
relating to access to such properties), except if and to the extent disclosed in the Registration Statement or Prospectus or except for
such failures to comply that would not, individually or in the aggregate, reasonably be expected to interfere in any material respect
with the use made and proposed to be made of such property by the Company and its Subsidiaries or otherwise have a Material Adverse Effect.
None of the Company or its subsidiaries has received from any Governmental Authorities any notice of any condemnation of, or zoning change
affecting, the properties of the Company and its Subsidiaries, and the Company knows of no such condemnation or zoning change which is
threatened, except for such that would not reasonably be expected to interfere in any material respect with the use made and proposed
to be made of such property by the Company and its Subsidiaries or otherwise have a Material Adverse Effect, individually or in the aggregate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(bb) <u>Environmental Laws</u>. Except as set forth in the Registration Statement or the Prospectus, the Company
and its Subsidiaries (i) are in compliance with any and all applicable federal, state, local and foreign laws, rules, regulations,
decisions and orders relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes,
pollutants or contaminants (collectively, "  **<u>Environmental Laws</u>** "); (ii) have received and are in compliance
with all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses
as described in the Registration Statement and the Prospectus; and (iii) have not received notice of any actual or potential liability
for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants,
except, in the case of any of clauses (i), (ii) or (iii) above, for any such failure to comply or failure to receive required permits,
licenses, other approvals or liability as would not, individually or in the aggregate, have a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(cc) <u>Disclosure Controls</u>. Except as disclosed in the Registration Statement or Prospectus, the Company
and each of its Subsidiaries maintain systems of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions
are executed in accordance with management's general or specific authorizations; (ii) transactions are recorded as necessary
to permit preparation of financial statements in conformity with IFRS and to maintain asset accountability; (iii) access to assets
is permitted only in accordance with management's general or specific authorization; and (iv) the recorded accountability for
assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Except
as disclosed in the Registration Statement or Prospectus, the Company's internal control over financial reporting is effective and
the Company is not aware of any material weaknesses in its internal control over financial reporting (other than as set forth in the Prospectus).
Since the date of the latest audited financial statements of the Company included in the Prospectus, there has been no change in the Company's
internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company's
internal control over financial reporting (other than as set forth in the Prospectus). The Company has established disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15) for the Company and designed such disclosure controls and procedures
to ensure that material information relating to the Company and each of its Subsidiaries is made known to the certifying officers by others
within those entities, particularly during the period in which the Company's Annual Report on Form 20-F is being prepared. The Company's
certifying officers have evaluated the effectiveness of the Company's disclosure controls and procedures as of a date within 90
days prior to the filing date of the Annual Report on Form 20-F for the fiscal year most recently ended (such date, the **" <u>Evaluation Date</u>** "). The Company presented in its Annual Report on Form 20-F for the fiscal year most recently ended the conclusions
of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation
Date and the disclosure controls and procedures are effective. Since the Evaluation Date, there have been no significant changes in the
Company's internal controls (as such term is defined in Item 307(b) of Regulation S-K under the Securities Act) or, to the Company's
knowledge, in other factors that could significantly affect the Company's internal controls.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(dd) <u>Sarbanes-Oxley</u>. There is and has been no failure on the part of the Company or, to the knowledge
of the Company, any of the Company's directors or officers, in their capacities as such, to comply in all material respects with
any applicable provisions of the Sarbanes-Oxley Act and the rules and regulations promulgated thereunder. Each of the principal executive
officer and the principal financial officer of the Company (or each former principal executive officer of the Company and each former
principal financial officer of the Company as applicable) has made all certifications required by Sections 302 and 906 of the Sarbanes-Oxley
Act with respect to all reports, schedules, forms, statements and other documents required to be filed by it or furnished by it to the
Commission. For purposes of the preceding sentence, "principal executive officer" and "principal financial officer"
shall have the meanings given to such terms in the Sarbanes-Oxley Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ee) <u>Finder's Fees</u>. Neither the Company nor any of the Subsidiaries has incurred any liability
for any finder's fees, brokerage commissions or similar payments in connection with the transactions herein contemplated, except
as may otherwise exist with respect to the Agent pursuant to this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ff) <u>Labor Disputes</u>. No labor disturbance by or dispute with employees of the Company or any of its
Subsidiaries exists or, to the knowledge of the Company, is threatened which would result in a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(gg) <u>Investment Company Act</u>. Neither the Company nor any of the Subsidiaries is or, after giving effect
to the offering and sale of the Placement Shares and the application of the proceeds thereof, will be an "investment company"
or an entity "controlled" by an "investment company," as such terms are defined in the Investment Company Act
of 1940, as amended (the "  **<u>Investment Company Act</u>** "). The Company shall conduct its business in a manner that
it will not become an "investment company" subject to registration under the Investment Company Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(hh) <u>Operations</u>. The operations of the Company and its Subsidiaries are and have been conducted at all
times in compliance with applicable financial record keeping and reporting requirements of the Currency and Foreign Transactions Reporting
Act of 1970, as amended, the money laundering statutes of all jurisdictions to which the Company or its Subsidiaries are subject, the
rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any
Governmental Authority (collectively, the "  **<u>Money Laundering Laws</u>** "), and no action, suit or proceeding by or
before any Governmental Authority involving the Company or any of its Subsidiaries with respect to the Money Laundering Laws is pending
or, to the knowledge of the Company, threatened.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) <u>Off-Balance Sheet Arrangements</u>. There are no transactions, arrangements and other relationships
between and/or among the Company, and/or any of its affiliates and any unconsolidated entity, including, but not limited to, any structured
finance, special purpose or limited purpose entity (each, an "  **<u>Off-Balance Sheet Transaction</u>**") that could reasonably
be expected to affect materially the Company's liquidity or the availability of or requirements for its capital resources, including
those Off-Balance Sheet Transactions described in the Commission's Statement about Management's Discussion and Analysis of
Financial Conditions and Results of Operations (Release Nos. 33-8056; 34-45321; FR-61), required to be described in the Prospectus which
have not been described as required.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(jj) <u>Underwriter Agreements</u>. The Company is not a party to any agreement with an agent or underwriter
for any other "at the market offering" or continuous equity transaction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(kk) <u>ERISA</u>. To the knowledge of the Company, (i) each material employee benefit plan, within the meaning
of Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended ("  **<u>ERISA</u>** "), that is maintained,
administered or contributed to by the Company or any of its affiliates for employees or former employees of the Company and any of its
Subsidiaries has been maintained in material compliance with its terms and the requirements of any applicable statutes, orders, rules
and regulations, including but not limited to ERISA and the Internal Revenue Code of 1986, as amended (the "  **<u>Code</u>** ");
(ii) no prohibited transaction, within the meaning of Section 406 of ERISA or Section 4975 of the Code, has occurred which would result
in a material liability to the Company with respect to any such plan excluding transactions effected pursuant to a statutory or administrative
exemption; and (iii) for each such plan that is subject to the funding rules of Section 412 of the Code or Section 302 of ERISA, no "accumulated
funding deficiency" as defined in Section 412 of the Code has been incurred, whether or not waived, and the fair market value of
the assets of each such plan (excluding for these purposes accrued but unpaid contributions) exceeds the present value of all benefits
accrued under such plan determined using reasonable actuarial assumptions, other than, in the case of (i), (ii) and (iii) above, as would
not have a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ll) <u>Forward-Looking Statements</u>. No forward-looking statement (within the meaning of Section 27A of
the Securities Act and Section 21E of the Exchange Act) (a "  **<u>Forward-Looking Statement</u>**") contained in the Registration
Statement and the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(mm) <u>Agent Purchases</u>. The Company acknowledges and agrees that the Agent has informed the Company that
the Agent may, to the extent permitted under the Securities Act and the Exchange Act, purchase and sell Ordinary Shares for its own account
while this Agreement is in effect, *provided*, that the Company shall not be deemed to have authorized or consented to any such purchases
or sales by the Agent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(nn) <u>Margin Rules</u>. Neither the issuance, sale and delivery of the Placement Shares nor the application
of the proceeds thereof by the Company as described in the Registration Statement and the Prospectus will violate Regulation T, U or X
of the Board of Governors of the Federal Reserve System or any other regulation of such Board of Governors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(oo) <u>Insurance</u>. The Company and each of its Subsidiaries carry, or are covered by, insurance in such
amounts and covering such risks as the Company and each of its Subsidiaries reasonably believe are adequate for the conduct of their properties
and as is customary for companies engaged in similar businesses in similar industries.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(pp) <u>No Improper Practices</u>. (i) Neither the Company nor the Subsidiaries, nor, to the knowledge
of the Company, any director, officer, or employee of the Company or any Subsidiary nor, to the Company's knowledge, any agent,
affiliate or other person acting on behalf of the Company or any Subsidiary has, in the past five years, made any unlawful contributions
to any candidate for any political office (or failed fully to disclose any contribution in violation of applicable law) or made any contribution
or other payment to any official of, or candidate for, any federal, state, municipal, or foreign office or other person charged with similar
public or quasi-public duty in violation of any applicable law or of the character required to be disclosed in the Prospectus; (ii) no
relationship, direct or indirect, exists between or among the Company or any Subsidiary or any affiliate of any of them, on the one hand,
and the directors, officers and shareholders of the Company or any Subsidiary, on the other hand, that is required by the Securities Act
to be described in the Registration Statement and the Prospectus that is not so described; (iii) no relationship, direct or indirect,
exists between or among the Company or any Subsidiary or any affiliate of them, on the one hand, and the directors, officers, or shareholders
of the Company or any Subsidiary, on the other hand, that is required by the rules of FINRA to be described in the Registration Statement
and the Prospectus that is not so described; (iv) except as described in the Registration Statement and the Prospectus, there are
no material outstanding loans or advances or material guarantees of indebtedness by the Company or any Subsidiary to or for the benefit
of any of their respective officers or directors or any of the members of the families of any of them; and (v) the Company has not offered,
or caused any placement agent to offer, Ordinary Shares to any person with the intent to influence unlawfully (A) a customer or supplier
of the Company or any Subsidiary to alter the customer's or supplier's level or type of business with the Company or any Subsidiary
or (B) a trade journalist or publication to write or publish favorable information about the Company or any Subsidiary or any of
their respective products or services, and, (vi) neither the Company nor any Subsidiary nor any director, officer or employee of the Company
or any Subsidiary nor, to the Company's knowledge, any agent, affiliate or other person acting on behalf of the Company or any Subsidiary
has (A) violated or is in violation of any applicable provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or any
other applicable anti-bribery or anti-corruption law (collectively, "  **<u>Anti-Corruption Laws</u>** "), (B) promised, offered,
provided, attempted to provide or authorized the provision of anything of value, directly or indirectly, to any person for the purpose
of obtaining or retaining business, influencing any act or decision of the recipient, or securing any improper advantage; or (C) made
any payment of funds of the Company or any Subsidiary or received or retained any funds in violation of any Anti-Corruption Laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(qq) <u>Status Under the Securities Act</u>. The Company was not and is not an ineligible issuer as defined
in Rule 405 under the Securities Act at the times specified in Rules 164 and 433 under the Securities Act in connection with the offering
of the Placement Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(rr) <u>No Misstatement or Omission in an Issuer Free Writing Prospectus</u>. Each Issuer Free Writing Prospectus,
as of its issue date and as of each Applicable Time (as defined in <u>Section 26</u> below), did not, does not and will not include any
information that conflicted, conflicts or will conflict with the information contained in the Registration Statement or the Prospectus,
including any incorporated document deemed to be a part thereof that has not been superseded or modified. The foregoing sentence does
not apply to statements in or omissions from any Issuer Free Writing Prospectus based upon and in conformity with written information
furnished to the Company by the Agent specifically for use therein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ss) <u>No Conflicts</u>. Neither the execution of this Agreement, nor the issuance, offering or sale of the
Placement Shares, nor the consummation of any of the transactions contemplated herein and therein, nor the compliance by the Company with
the terms and provisions hereof and thereof will conflict with, or will result in a breach of, any of the terms and provisions of, or
has constituted or will constitute a default under, or has resulted in or will result in the creation or imposition of any lien, charge
or encumbrance upon any property or assets of the Company pursuant to the terms of any contract or other agreement to which the Company
may be bound or to which any of the property or assets of the Company is subject, except (i) such conflicts, breaches or defaults as may
have been waived and (ii) such conflicts, breaches and defaults that would not have a Material Adverse Effect; nor will such action result
(x) in any violation of the provisions of the organizational or governing documents of the Company, or (y) in any material violation of
the provisions of any statute or any order, rule or regulation applicable to the Company or of any Governmental Authority having jurisdiction
over the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(tt) <u>Sanctions</u>. (i) The Company represents that neither the Company nor any of its Subsidiaries (collectively,
the "  **<u>Entity</u>**") or any director, officer, employee, agent, affiliate or representative of the Entity, is a government,
individual, or entity (in this paragraph (vv), "  **<u>Person</u>**") that is, or is owned or controlled by a Person that
is:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) the subject of any sanctions administered or enforced by the U.S. Department of the Treasury's Office of Foreign Assets Control ("**<u>OFAC</u>**"), the United Nations Security Council, the European Union, His Majesty's Treasury, or other relevant sanctions authorities, including, without limitation, designation on OFAC's Specially Designated Nationals and Blocked Persons List or OFAC's Foreign Sanctions Evaders List (as amended, collectively, "**<u>Sanctions</u>**"), nor

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) located, organized or resident in a country or territory that is the subject of Sanctions that broadly prohibit dealings with that country or territory (including, without limitation, Cuba, Iran, North Korea, Syria, the so-called Donetsk People's Republic, the so-called Luhansk People's Republic and the Crimea Region of Ukraine) (the "**Sanctioned Countries**").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) The Company represents and covenants that the Entity will not, directly or indirectly knowingly, use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other Person:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) to fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding or facilitation, is the subject of Sanctions or is a Sanctioned Country; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) in any other manner that will result in a violation of Sanctions by any Person (including any Person participating in the offering, whether as underwriter, advisor, investor or otherwise).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) The Company represents and covenants that, except as detailed in the Registration Statement and the Prospectus, since April 24, 2019, the Entity has not engaged in, is not now engaging in, and will not engage in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions or is or was a Sanctioned Country.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(uu) <u>Stock Transfer Taxes</u>. On each Settlement Date, all material stock transfer or other taxes (other
than income taxes) which are required to be paid in connection with the sale and transfer of the Placement Shares to be sold hereunder
will be, or will have been, fully paid or provided for by the Company and all laws imposing such taxes will be or will have been fully
complied with in all material respects.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vv) <u>Compliance with Laws</u>. The Company and each of its Subsidiaries are in compliance with all applicable
laws, regulations and statutes (including all environmental laws and regulations) in the jurisdictions in which it carries on business;
the Company has not received a notice of non-compliance, nor knows of, nor has reasonable grounds to know of, any facts that could give
rise to a notice of non-compliance with any such laws, regulations and statutes, and is not aware of any pending change or contemplated
change to any such applicable law or regulation or statutes; in each case that would materially adversely affect the business of the Company
or the business or legal environment under which the Company operates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ww) <u>Statistical and Market-Related Data</u>. The statistical, demographic and market-related data
included in the Registration Statement and Prospectus are based on or derived from sources that the Company believes to be reliable and
accurate or represent the Company's good faith estimates that are made on the basis of data derived from such sources.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xx) <u>Cybersecurity</u>. Except as would not reasonably be expected, individually or in the aggregate, to
have a Material Adverse Effect, the Company and its Subsidiaries' information technology assets and equipment, computers, systems,
networks, hardware, software, websites, applications, and databases (collectively, "  **<u>IT Systems</u>**") are adequate
for, and operate and perform in all material respects as required in connection with the operation of the business of the Company as currently
conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. Except as would
not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, the Company and its Subsidiaries have
implemented and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards
to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all
IT Systems and data, including all "Personal Data" (as defined below) and all sensitive, confidential or regulated data ("  **<u>Confidential Data</u>**") used in connection with their businesses. "Personal Data" means (i) a natural person's name, street
address, telephone number, e-mail address, photograph, social security number or tax identification number, driver's license number,
passport number, credit card number, bank information, or customer or account number; (ii) any information which would qualify as "personally
identifying information" under the Federal Trade Commission Act, as amended; (iii) "personal data" as defined by the
European Union General Data Protection Regulation ("  **<u>GDPR</u>**") (EU 2016/679); (iv) any information which would qualify
as "protected health information" under the Health Insurance Portability and Accountability Act of 1996, as amended by the
Health Information Technology for Economic and Clinical Health Act (collectively, "  **<u>HIPAA</u>** "); (v) any "personal
information" as defined by the California Consumer Privacy Act ("  **<u>CCPA</u>** "); and (vi) any other piece of information
that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related
to an identified person's health or sexual orientation. There have been no breaches, violations, outages or unauthorized uses of
or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person,
nor any incidents under internal review or investigations relating to the same. The Company and its Subsidiaries are presently in material
compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental
or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems, Confidential
Data, and Personal Data and to the protection of such IT Systems, Confidential Data, and Personal Data from unauthorized use, access,
misappropriation or modification.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(yy) <u>Compliance with Data Privacy Laws</u>. The Company and its Subsidiaries are, and at all prior times
were, in material compliance with all applicable state and federal data privacy and security laws and regulations, including without limitation
HIPAA, CCPA, and GDPR (collectively, the "  **<u>Privacy Laws</u>** "). To ensure compliance with the Privacy Laws, the Company
has in place, complies with, and takes appropriate steps to ensure compliance in all material respects with their policies and procedures
relating to data privacy and security and the collection, storage, use, processing, disclosure, handling, and analysis of Personal Data
and Confidential Data (the "  **<u>Policies</u>** "). The Company has at all times made all disclosures to users or customers
required by applicable laws and regulatory rules or requirements, and none of such disclosures made or contained in any Policy have been
inaccurate or in violation of any applicable laws and regulatory rules or requirements in any material respect. The Company further certifies
that neither it nor any Subsidiary: (i) has received notice of any actual or potential liability under or relating to, or actual or potential
violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected to result in any
such notice; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action
pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement that imposes any obligation or liability under any
Privacy Law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(zz) <u>Emerging Growth Company Status</u>. From the time of the initial filing of the Company's first
registration statement with the Commission through the date hereof, the Company has been and is an "emerging growth company,"
as defined in Section 2(a) of the Securities Act (an "  **<u>Emerging Growth Company</u>** ").

Any certificate signed by an officer of the Company and delivered to the Agent or to counsel for the Agent pursuant to or in connection with this Agreement shall be deemed to be a representation and warranty by the Company, as applicable, to the Agent as to the matters set forth therein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. <u>Covenants of the Company</u>. The Company covenants and agrees with the Agent that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Registration Statement Amendments</u>. After the date of this Agreement and during any period in which
a Prospectus relating to any Placement Shares is required to be delivered by the Agent under the Securities Act (including in circumstances
where such requirement may be satisfied pursuant to Rule 172 under the Securities Act or similar rule), (i) the Company will notify
the Agent promptly of the time when any subsequent amendment to the Registration Statement, other than documents incorporated by reference,
has been filed with the Commission and/or has become effective or any subsequent supplement to the Prospectus has been filed and of any
request by the Commission for any amendment or supplement to the Registration Statement or Prospectus or for additional information, (ii) the
Company will prepare and file with the Commission, promptly upon the Agent's request, any amendments or supplements to the Registration
Statement or Prospectus that, in the Agent's reasonable opinion, may be necessary or advisable in connection with the distribution
of the Placement Shares by the Agent (*provided*, *however*, that (A) the failure of the Agent to make such request shall not
relieve the Company of any obligation or liability hereunder, or affect the Agent's right to rely on the representations and warranties
made by the Company in this Agreement, and (B) the Company has no obligation to provide the Agents any such advanced copy or provide the
Agents an opportunity to object to the same if the filing does not name the Agents or does not relate to the transactions herein provided;
and *provided, further*, that the only remedy the Agent shall have with respect to the failure to make such filing shall be to cease
making sales under this Agreement until such amendment or supplement is filed); (iii) the Company will not file any amendment or
supplement to the Registration Statement or Prospectus relating to the Placement Shares or a security convertible into the Placement Shares
unless a copy thereof has been submitted to the Agent within a reasonable period of time before the filing and the Agent has not objected
thereto (*provided*, *however*, that the failure of the Agent to make such objection shall not relieve the Company of any obligation
or liability hereunder, or affect the Agent's right to rely on the representations and warranties made by the Company in this Agreement
and *provided*, *further*, that the only remedy the Agent shall have with respect to the failure by the Company to obtain such
consent shall be to cease making sales under this Agreement) and the Company will furnish to the Agent at the time of filing thereof a
copy of any document that upon filing is deemed to be incorporated by reference into the Registration Statement or Prospectus, except
for those documents available via EDGAR; and (iv) the Company will cause each amendment or supplement to Prospectus to be filed with
the Commission as required pursuant to the applicable paragraph of Rule 424(b) of the Securities Act or, in the case of any document to
be incorporated therein by reference, to be filed with the Commission as required pursuant to the Exchange Act, within the time period
prescribed (the determination to file or not file any amendment or supplement with the Commission under this <u>Section 7(a)</u>, based
on the Company's reasonable opinion or reasonable objections, shall be made exclusively by the Company).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Notice of Commission Stop Orders</u>. The Company will advise the Agent, promptly after it receives
notice or obtains knowledge thereof, of the issuance or threatened issuance by the Commission of any stop order suspending the effectiveness
of the Registration Statement, of the suspension of the qualification of the Placement Shares for offering or sale in any jurisdiction,
or of the initiation or threatening of any proceeding for any such purpose; and it will promptly use its commercially reasonable efforts
to prevent the issuance of any stop order or to obtain its withdrawal if such a stop order should be issued. The Company will advise the
Agent promptly after it receives any request by the Commission for any amendments to the Registration Statement or any amendment or supplements
to the Prospectus or any Issuer Free Writing Prospectus or for additional information related to the offering of the Placement Shares
or for additional information related to the Registration Statement, the Prospectus or any Issuer Free Writing Prospectus.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Delivery of Prospectus; Subsequent Changes</u>. During any period in which a Prospectus relating to
the Placement Shares is required to be delivered by the Agent under the Securities Act with respect to the offer and sale of the Placement
Shares, (including in circumstances where such requirement may be satisfied pursuant to Rule 172 under the Securities Act or similar rule),
the Company will comply in all material respects with all requirements imposed upon it by the Securities Act, as from time to time in
force, and to file on or before their respective due dates all reports and any definitive proxy or information statements required to
be filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14, 15(d) or any other provision of or under the Exchange
Act. If the Company has omitted any information from the Registration Statement pursuant to Rule 430B under the Securities Act, it will
use its reasonable best efforts to comply with the provisions of and make all requisite filings with the Commission pursuant to said Rule
430B and to notify the Agent promptly of all such filings. If during such period (i) any event occurs as a result of which the Prospectus
as then amended or supplemented would include an untrue statement of a material fact or omit to state a material fact necessary to make
the statements therein, in the light of the circumstances then existing, not misleading, or (ii) for any other reason it shall be necessary
during such same period to amend or supplement the Prospectus, to file any post-effective amendment to the Registration Statement or to
file under the Exchange Act any document incorporated by reference in the Prospectus in order to comply with the Securities Act or the
Exchange Act, the Company will promptly notify the Agent to suspend the offering of Placement Shares during such period and the Company
will promptly amend or supplement the Registration Statement or the Prospectus (at the expense of the Company) so as to correct such statement
or omission or effect such compliance and to prepare and furnish without charge to the Agent and to any dealer in securities as many written
and electronic copies as the Agent may from time to time reasonably request of an amended Prospectus or a supplement to the Prospectus
which will correct such statement or omission or effect such compliance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Listing of Placement Shares</u>. Prior to the date of the first Placement Notice, the Company will
use its reasonable best efforts to cause the Placement Shares to be listed on the Exchange.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Delivery of Registration Statement and Prospectus</u>. The Company will furnish to the Agent and its
counsel (at the expense of the Company) copies of the Registration Statement, the Prospectus (including all documents incorporated by
reference therein) and all amendments and supplements to the Registration Statement or Prospectus that are filed with the Commission during
any period in which a Prospectus relating to the Placement Shares is required to be delivered under the Securities Act (including all
documents filed with the Commission during such period that are deemed to be incorporated by reference therein), in each case as soon
as reasonably practicable and in such quantities as the Agent may from time to time reasonably request and, at the Agent's request,
will also furnish copies of the Prospectus to each exchange or market on which sales of the Placement Shares may be made; *provided*, *however*, that the Company shall not be required to furnish any document (other than the Prospectus) to the Agent to the extent
such document is available on EDGAR.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Earnings Statement</u>. The Company will make generally available to its security holders as soon as
practicable, but in any event not later than 15 months after the end of the Company's current fiscal quarter, an earnings statement
covering a 12-month period that satisfies the provisions of Section 11(a) and Rule 158 of the Securities Act. The Company's compliance
with the periodic reporting requirements of the Exchange Act shall be deemed to satisfy the requirements of this Section 7(f) Earnings
Statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <u>Use of Proceeds</u>. The Company will use the Net Proceeds as described in the Prospectus in the section
entitled "Use of Proceeds."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <u>Notice of Other Sales</u>. Without the prior written consent of the Agent, the Company will not, directly
or indirectly, offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Ordinary Shares (other than
the Placement Shares offered pursuant to this Agreement) or securities convertible into or exchangeable for Ordinary Shares, warrants
or any rights to purchase or acquire, Ordinary Shares during the period beginning on the fifth (5<sup>th</sup>) Trading Day immediately
prior to the date on which any Placement Notice is delivered to the Agent hereunder and ending on the fifth (5<sup>th</sup>) Trading Day
immediately following the final Settlement Date with respect to Placement Shares sold pursuant to such Placement Notice (or, if the Placement
Notice has been terminated or suspended prior to the sale of all Placement Shares covered by a Placement Notice, the date of such suspension
or termination); and will not directly or indirectly in any other "at the market" or continuous equity transaction offer to
sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Ordinary Shares (other than the Placement Shares offered
pursuant to this Agreement) or securities convertible into or exchangeable for Ordinary Shares, warrants or any rights to purchase or
acquire, Ordinary Shares prior to the sixtieth (60<sup>th</sup>) day immediately following the termination of this Agreement; *provided*, *however*, that such restrictions will not be required in connection with the Company's issuance or sale of (i) Ordinary
Shares, options to purchase Ordinary Shares or Ordinary Shares issuable upon the exercise of options, pursuant to any employee or director
stock option or benefits plan, stock ownership plan or dividend reinvestment plan (but not Ordinary Shares subject to a waiver to exceed
plan limits in its dividend reinvestment plan) of the Company whether now in effect or hereafter implemented, (ii) Ordinary Shares
issuable upon conversion of securities or the exercise of warrants, options or other rights in effect or outstanding, and disclosed in
filings by the Company available on EDGAR or otherwise in writing to the Agent and (iii) Ordinary Shares or securities convertible into
or exchangeable for Ordinary Shares as consideration for mergers, acquisitions, other business combinations or strategic alliances occurring
after the date of this Agreement which are not issued for capital raising purposes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>Change of Circumstances</u>. The Company will, at any time during the pendency of a Placement Notice,
advise the Agent promptly after it shall have received notice or obtained knowledge thereof, of any information or fact that would alter
or affect in any material respect any opinion, certificate, letter or other document required to be provided to the Agent pursuant to
this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) <u>Due Diligence Cooperation</u>. During the term of this Agreement, the Company will cooperate with any
reasonable due diligence review conducted by the Agent or its representatives in connection with the transactions contemplated hereby,
including, without limitation, providing information and making available documents and senior corporate officers, during regular business
hours and at the Company's principal offices, as the Agent may reasonably request.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) <u>Required Filings Relating to Placement of Placement Shares</u>. The Company shall disclose, in its
Reports of Foreign Private Issuer on Form 6-K containing its semi-annual financial statements and in its Annual Report on Form 20-F to
be filed by the Company with the Commission from time to time, the number of the Placement Shares sold through the Agent under this Agreement,
and the net proceeds to the Company from the sale of the Placement Shares pursuant to this Agreement during the relevant semi-annual period
or, in the case of an Annual Report on Form 20-F, during the fiscal year covered by such Annual Report and the fourth quarter of such
fiscal year. The Company agrees that on such dates as the Securities Act shall require, the Company will (i) file a prospectus supplement
with the Commission under the applicable paragraph of Rule 424(b) under the Securities Act (each and every filing date under Rule 424(b),
a "  **<u>Filing Date</u>** "), which prospectus supplement will set forth, within the relevant period, the amount of Placement
Shares sold through the Agent, the Net Proceeds to the Company and the compensation payable by the Company to the Agent with respect to
such Placement Shares), and (ii) deliver such number of copies of each such prospectus supplement to each exchange or market on which
such sales were effected as may be required by the rules or regulations of such exchange or market; provided, however, that no such filing
shall be required if the Company shall have disclosed such information in its most recent periodic report filed pursuant to the Exchange
Act, and such disclosure is sufficient pursuant to the Exchange Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) <u>Representation Dates; Certificate</u>. (1) Prior to the date of the first Placement Notice and (2)
each time the Company:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) files the Prospectus relating to the Placement Shares or amends or supplements (other than a prospectus supplement relating solely to an offering of securities other than the Placement Shares) the Registration Statement or the Prospectus relating to the Placement Shares by means of a post-effective amendment, sticker, or supplement but not by means of incorporation of documents by reference into the Registration Statement or the Prospectus relating to the Placement Shares;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) files an Annual Report on Form 20-F under the Exchange Act (including any Annual Report on Form 20-F/A containing amended financial information or a material amendment to the previously filed Form 20-F);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) furnishes its Reports of Foreign Private Issuer on Form 6-K under the Exchange Act containing semi-annual or quarterly financial statements; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) furnishes a Report of Foreign Private Issuer on Form 6-K containing amended financial information under the Exchange Act (each date of filing of one or more of the documents referred to in clauses (i) through (iv) shall be a "**<u>Representation Date</u>**");

the Company shall furnish the Agent (but in the case of clause (iv) above only if the Agent reasonably determines that the information contained in such Report of Foreign Private Issuer on Form 6-K is material) with a certificate dated the Representation Date, in the form and substance satisfactory to the Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel, modified, as necessary, to relate to the Registration Statement and the Prospectus as amended or supplemented. The requirement to provide a certificate under this <u>Section 7(l)</u> shall be waived for any Representation Date occurring at a time a Suspension is in effect, which waiver shall continue until the earlier to occur of the date the Company delivers instructions for the sale of Placement Shares hereunder (which for such calendar quarter shall be considered a Representation Date) and the next occurring Representation Date. Notwithstanding the foregoing, if the Company subsequently decides to sell Placement Shares following a Representation Date when a Suspension was in effect and did not provide the Agent with a certificate under this <u>Section 7(l)</u>, then before the Company delivers the instructions for the sale of Placement Shares or the Agent sells any Placement Shares pursuant to such instructions, the Company shall provide the Agent with a certificate in conformity with this <u>Section 7(l)</u> dated as of the date that the instructions for the sale of Placement Shares are issued.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) <u>Legal Opinion</u>. (1) Prior to the date of the first Placement Notice and (2) within five (5) Trading
Days of each Representation Date with respect to which the Company is obligated to deliver a certificate pursuant to <u>Section 7(l)</u> for which no waiver is applicable and excluding the date of this Agreement, the Company shall cause to be furnished to the Agent a written
opinion and negative assurance letter of Lowenstein Sandler LLP ("  **<u>Company Counsel</u>**") and a written opinion of
Clark Hill Solicitors LLP ("  **<u>Local Company Counsel</u>** "), or other counsel satisfactory to the Agent, each in form
and substance satisfactory to the Agent and its counsel; *provided*, that in lieu of such opinions or negative assurance letter for
subsequent periodic filings under the Exchange Act, each counsel may furnish the Agent with a letter (a "  **<u>Reliance Letter</u>** ")
to the effect that the Agent may rely on a prior opinion or negative assurance letter delivered under this <u>Section 7(m)</u> to the
same extent as if it were dated the date of such letter (except that statements in such prior opinion or negative assurance letter, as
the case may be, shall be deemed to relate to the Registration Statement and the Prospectus as amended or supplemented as of the date
of the Reliance Letter).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n) <u>Comfort Letter</u>. (1) Prior to the date of the first Placement Notice and (2) within five (5) Trading
Days of each Representation Date with respect to which the Company is obligated to deliver a certificate pursuant to <u>Section 7(l)</u> for which no waiver is applicable and excluding the date of this Agreement, the Company shall cause its independent registered public
accounting firm (and any other independent accountant whose report is included in or incorporated by reference into the Registration Statement
or Prospectus) to furnish the Agent letters (the "  **<u>Comfort Letters</u>** "), dated the date the Comfort Letter is delivered,
which shall meet the requirements set forth in this <u>Section 7(n)</u>; *provided*, that if requested by the Agent, the Company
shall cause a Comfort Letter to be furnished to the Agent within ten (10) Trading Days after the date of occurrence of any material transaction
or event, including the restatement of the Company's financial statements, provided, however, that the requirement to provide such
additional Comfort Letter shall be waived for any time a Placement Notice is not pending or a Suspension is in effect, which waiver shall
continue until the earlier to occur of the date the Company delivers instructions for the sale of Placement Shares hereunder and the next
occurring Representation Date. The Comfort Letter from the Company's independent registered public accounting firm (and any other
independent accountant whose report is included in or incorporated by reference into the Registration Statement or the Prospectus) shall
be in a form and substance satisfactory to the Agent, (i) confirming that they are an independent registered public accounting firm within
the meaning of the Securities Act and the Public Company Accounting Oversight Board ("  **<u>PCAOB</u>** "), (ii) stating,
as of such date, the conclusions and findings of such firm with respect to the financial information and other matters ordinarily covered
by accountants' "comfort letters" to underwriters in connection with registered public offerings (the first such letter,
the "  **<u>Initial Comfort Letter</u>**") and (iii) updating the Initial Comfort Letter with any information that would
have been included in the Initial Comfort Letter had it been given on such date and modified as necessary to relate to the Registration
Statement and the Prospectus, as amended and supplemented to the date of such letter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o) <u>Market Activities; Compliance with Regulation M</u>. The Company will not, directly or indirectly,
(i) take any action designed to cause or result in, or that constitutes or would reasonably be expected to constitute, the stabilization
or manipulation of the price of any security of the Company to facilitate the sale or resale of Ordinary Shares or (ii) sell, bid
for, or purchase Ordinary Shares in violation of Regulation M, or pay anyone any compensation for soliciting purchases of the Placement
Shares other than the Agent; provided, however, that this Section 7(p) Market Activities; Compliance with Regulation M shall not restrict
the Company from bidding for and purchasing shares of Class A Common Stock in accordance with Rule 10b-18 under the Exchange Act..

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p) <u>Investment Company Act</u>. The Company will conduct its affairs in such a manner so as to reasonably
ensure that neither it nor any of its Subsidiaries will be or become, at any time prior to the termination of this Agreement, required
to register as an "investment company," as such term is defined in the Investment Company Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q) <u>No Offer to Sell</u>. Other than an Issuer Free Writing Prospectus approved in advance by the Company
and the Agent in its capacity as agent hereunder, neither the Agent nor the Company (including its agents and representatives, other than
the Agent in its capacity as such) will make, use, prepare, authorize, approve or refer to any written communication (as defined in Rule
405 under the Securities Act), required to be filed with the Commission, that constitutes an offer to sell or solicitation of an offer
to buy Placement Shares hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(r) <u>Blue Sky and Other Qualifications</u> *.* The Company will use its commercially reasonable efforts,
in cooperation with the Agent, to qualify the Placement Shares for offering and sale, or to obtain an exemption for the Placement Shares
to be offered and sold, under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as the Agent
may designate and to maintain such qualifications and exemptions in effect for so long as required for the distribution of the Placement
Shares (but in no event for less than one year from the date of this Agreement); *provided*, *however*, that the Company shall
not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a dealer in securities
in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction
in which it is not otherwise so subject. In each jurisdiction in which the Placement Shares have been so qualified or exempt, the Company
will file such statements and reports as may be required by the laws of such jurisdiction to continue such qualification or exemption,
as the case may be, in effect for so long as required for the distribution of the Placement Shares (but in no event for less than one
year from the date of this Agreement).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(s) <u>Sarbanes-Oxley Act</u>. The Company and the Subsidiaries will maintain and keep accurate books and
records reflecting their assets and maintain internal accounting controls in a manner designed to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS and including
those policies and procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect
the transactions and dispositions of the assets of the Company, (ii) provide reasonable assurance that transactions are recorded
as necessary to permit the preparation of the Company's consolidated financial statements in accordance with IFRS, (iii) that
receipts and expenditures of the Company are being made only in accordance with management's and the Company's directors'
authorization, and (iv) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or
disposition of the Company's assets that could have a material effect on its financial statements. The Company and the Subsidiaries
will maintain such controls and other procedures, including, without limitation, those required by Sections 302 and 906 of the Sarbanes-Oxley
Act, and the applicable regulations thereunder that are designed to ensure that information required to be disclosed by the Company in
the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified
in the Commission's rules and forms, including, without limitation, controls and procedures designed to ensure that information
required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated
to the Company's management, including its principal executive officer and principal financial officer, or persons performing similar
functions, as appropriate to allow timely decisions regarding required disclosure and to ensure that material information relating to
the Company or the Subsidiaries is made known to them by others within those entities, particularly during the period in which such periodic
reports are being prepared.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(t) <u>Secretary's Certificate; Further Documentation</u>. Prior to the date of the first Placement
Notice, the Company shall deliver to the Agent a certificate of the Secretary of the Company and attested to by an executive officer of
the Company, dated as of such date, certifying as to (i) the constitution of the Company, (ii) the resolutions of the Board of Directors
of the Company authorizing the execution, delivery and performance of this Agreement and the issuance of the Placement Shares and (iii)
the incumbency of the officers duly authorized to execute this Agreement and the other documents contemplated by this Agreement. Within
five (5) Trading Days of each Representation Date, the Company shall have furnished to the Agent such further information, certificates
and documents as the Agent may reasonably request.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(u) <u>Emerging Growth Company Status</u>. The Company will promptly notify the Agent if the Company ceases
to be an Emerging Growth Company at any time during the term of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) <u>Submission to Jurisdiction</u>. The Company has the power to submit, and pursuant to <u>Section 18</u> of this Agreement, has legally, validly, effectively and irrevocably submitted, to the personal jurisdiction of each United States federal
court and New York state court located in the City and County of New York, Borough of Manhattan, State of New York, U.S.A., and the Company
has the power to designate and pursuant to <u>Section 18</u> of this Agreement, has legally, validly, effectively and irrevocably designated
the notice address provided in <u>Section 13</u> of this Agreement for the effective service of process in any action arising out of or
relating to this Agreement or the Securities in any of the above courts, and service of process effected on such address will be effective
to confer valid personal jurisdiction over the Company as provided in <u>Section 18</u> hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(w) <u>No Rights of Immunity</u>. Except as provided by laws or statutes generally applicable to transactions
of the type described in this Agreement, neither the Company nor any of its respective properties, assets or revenues has any right of
immunity under the laws of Ireland, New York State law or United States federal law, from any legal action, suit or proceeding, from the
giving of any relief in any such legal action, suit or proceeding, from set-off or counterclaim, from the jurisdiction of any Ireland,
New York or United States federal court, from service of process, attachment upon or prior to judgment, or attachment in aid of execution
of judgment, or from execution of a judgment, or other legal process or proceeding for the giving of any relief or for the enforcement
of a judgment, in any such court, with respect to its obligations, liabilities or any other matter under or arising out of or in connection
with this Agreement. To the extent that the Company or any of its respective properties, assets or revenues may have or may hereafter
become entitled to any such right of immunity in any such court in which proceedings may at any time be commenced, the Company waives
or will waive such right to the extent permitted by law and has consented to such relief and enforcement as provided in <u>Section 17</u> and <u>Section 18</u> of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. <u>Payment of Expenses</u>. The Company will pay all expenses
incident to the performance of its obligations under this Agreement, including (i) the preparation and filing of the Registration
Statement, including any fees required by the Commission, and the printing or electronic delivery of the Prospectus as originally filed
and of each amendment and supplement thereto, in such number as the Agent shall deem necessary, (ii) the printing and delivery to the
Agent of this Agreement and such other documents as may reasonably be required in connection with the offering, purchase, sale, issuance
or delivery of the Placement Shares, (iii) the preparation, issuance and delivery of the certificates, if any, for the Placement
Shares to the Agent, including any stock or other transfer taxes and any capital duties, stamp duties or other duties or taxes payable
upon the sale, issuance or delivery of the Placement Shares to the Agent, (iv) the fees and disbursements of the counsel, accountants
and other advisors to the Company, (v) the fees and expenses of the Agent including but not limited to the fees and expenses of
the counsel to the Agent, payable upon the execution of this Agreement, (a) in an amount not to exceed $150,000 in the aggregate in connection
with the execution of this Agreement, (b) in an amount not to exceed $25,000 in the aggregate per calendar quarter thereafter payable
in connection with each Representation Date with respect to which the Company is obligated to deliver a certificate pursuant to <u>Section 7(l)</u> for which no waiver is applicable and excluding the date of this Agreement, and (c) in an amount not to exceed $40,000 in the
aggregate for each program "refresh" (filing of a new registration statement, prospectus or prospectus supplement relating
to the Placement Shares and/or an amendment of this Agreement) executed pursuant to this Agreement, (vi) the qualification or exemption
of the Placement Shares under state securities laws in accordance with the provisions of <u>Section 7(r)</u> hereof, including filing
fees, but excluding fees of the Agent's counsel, (vii) the printing and delivery to the Agent of copies of any Permitted Issuer
Free Writing Prospectus and the Prospectus and any amendments or supplements thereto in such number as the Agent shall deem necessary,
(viii) the preparation, printing and delivery to the Agent of copies of the blue sky survey, (ix) the fees and expenses of
the transfer agent and registrar for the Ordinary Shares, (x) the filing and other fees incident to any review by FINRA of the terms
of the sale of the Placement Shares including the fees of the Agent's counsel (subject to the cap, set forth in clause (v) above),
and (xi) the fees and expenses incurred in connection with the listing of the Placement Shares on the Exchange. The Company agrees
to pay the fees and expenses of counsel to the Agent set forth in clause (v) above by wire transfer of immediately available funds directly
to such counsel reasonably promptly following presentation of an invoice containing the requisite payment information prepared by such
counsel, and such counsel shall be a third-party beneficiary of the expense reimbursement obligations set forth in this Section 8.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. <u>Conditions to the Agent's Obligations</u>. The obligations of the Agent hereunder with respect
to a Placement will be subject to the continuing accuracy and completeness of the representations and warranties made by the Company herein
(other than those representations and warranties made as of a specified date or time) in all material respects, to the due performance
in all material respects by the Company of its obligations hereunder, to the completion by the Agent of a due diligence review satisfactory
to it in its reasonable judgment, and to the continuing satisfaction (or waiver by the Agent in its sole discretion) of the following
additional conditions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Registration Statement Effective</u>. The Registration Statement shall have become effective and shall
be available for the (i) resale of all Placement Shares issued to the Agent and not yet sold by the Agent and (ii) sale of all Placement
Shares contemplated to be issued by any Placement Notice.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>No Material Notices</u>. None of the following events shall have occurred and be continuing: (i) receipt
by the Company of any request for additional information from the Commission or any other federal or state Governmental Authority during
the period of effectiveness of the Registration Statement, the response to which would require any post-effective amendments or supplements
to the Registration Statement or the Prospectus; (ii) the issuance by the Commission or any other federal or state Governmental Authority
of any stop order suspending the effectiveness of the Registration Statement or the initiation of any proceedings for that purpose; (iii) receipt
by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Placement
Shares for sale in any jurisdiction or the initiation or threatening in writing of any proceeding for such purpose; or (iv) the occurrence
of any event that makes any statement of a material fact made in the Registration Statement or the Prospectus or any document incorporated
or deemed to be incorporated therein by reference untrue in any material respect or that requires the making of any changes in the Registration
Statement, the Prospectus or any such documents so that, in the case of the Registration Statement, it will not contain an untrue statement
of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading
and, that in the case of the Prospectus, it will not contain an untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made,
not misleading.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>No Misstatement or Material Omission</u>. The Agent shall not have advised the Company that the Registration
Statement or Prospectus, or any amendment or supplement thereto, contains an untrue statement of fact that in the Agent's reasonable
opinion is material, or omits to state a fact that in the Agent's reasonable opinion is material and is required to be stated therein
or is necessary to make the statements therein not misleading.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Material Changes</u>. Except as contemplated in the Prospectus, or disclosed in the Company's
reports filed with the Commission, there shall not have been any material adverse change in the authorized shares of the Company or any
Material Adverse Effect or any development that would cause a Material Adverse Effect, or a downgrading in or withdrawal of the rating
assigned to any of the Company's securities (other than asset backed securities) by any rating organization or a public announcement
by any rating organization that it has under surveillance or review its rating of any of the Company's securities (other than asset
backed securities), the effect of which, in the case of any such action by a rating organization described above, in the reasonable judgment
of the Agent (without relieving the Company of any obligation or liability it may otherwise have), is so material as to make it impracticable
or inadvisable to proceed with the offering of the Placement Shares on the terms and in the manner contemplated in the Prospectus.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Legal Opinions</u>. The Agent shall have received the opinions and negative assurance letters required
to be delivered pursuant to <u>Section 7(m)</u> on or before the date on which such delivery of such opinions and negative assurance letter,
as applicable, is required pursuant to <u>Section 7(m)</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Comfort Letter</u>. The Agent shall have received the Comfort Letters required to be delivered pursuant
to <u>Section 7(n)</u> on or before the date on which such delivery of such Comfort Letters is required pursuant to <u>Section 7(n)</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <u>Representation Certificate</u>. The Agent shall have received the certificate required to be delivered
pursuant to <u>Section 7(l)</u> on or before the date on which delivery of such certificate is required pursuant to <u>Section 7(l)</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <u>No Suspension</u>. Trading in the Ordinary Shares shall not have been suspended on the Exchange and
the Ordinary Shares shall not have been delisted from the Exchange.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>Other Materials</u>. On each date on which the Company is required to deliver a certificate pursuant
to <u>Section 7(l)</u>, the Company shall have furnished to the Agent such appropriate further information, opinions, certificates, letters
and other documents as the Agent may reasonably request and which are usually and customarily furnished by an issuer of securities in
connection with a securities offering of the type contemplated hereby. All such opinions, certificates, letters and other documents will
be in compliance with the provisions hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) <u>Securities Act Filings Made</u>. All filings with the Commission required by Rule 424 under the Securities
Act to have been filed prior to the issuance of any Placement Notice hereunder shall have been made within the applicable time period
prescribed for such filing by Rule 424.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) <u>Approval for Listing</u>. The Placement Shares shall either have been (i) approved for listing on the
Exchange, subject only to notice of issuance, or (ii) the Company shall have filed an application for listing of the Placement Shares
on the Exchange at, or prior to, the issuance of any Placement Notice and the Exchange shall have reviewed such application and not provided
any objections thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) <u>FINRA</u>. If applicable, FINRA shall have raised no objection to the terms of this offering and the
amount of compensation allowable or payable to the Agent as described in the Prospectus.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) <u>No Termination Event</u>. There shall not have occurred any event that would permit the Agent to terminate
this Agreement pursuant to <u>Section 12(a)</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. <u>Indemnification and Contribution</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Company Indemnification</u>. The Company agrees to indemnify
and hold harmless the Agent, its affiliates and their respective partners, members, directors, officers, employees and agents and each
person, if any, who controls the Agent or any affiliate within the meaning of Section 15 of the Securities Act or Section 20
of the Exchange Act as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) against any and all loss, liability, claim, damage and reasonable and documented expense whatsoever, as incurred, joint or several, arising out of or based upon any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment thereto), or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading, or arising out of any untrue statement or alleged untrue statement of a material fact included in any related Issuer Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) against any and all loss, liability, claim, damage and reasonable and documented expense whatsoever, as incurred, joint or several, to the extent of the aggregate amount paid in settlement of any litigation, or any investigation or proceeding by any Governmental Authority, commenced or threatened, or of any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission; *provided* that (subject to <u>Section 10(d)</u> below) any such settlement is effected with the written consent of the Company, which consent shall not unreasonably be delayed or withheld; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) against any and all reasonable and documented expense whatsoever, as incurred (including the reasonable and documented out of pocket fees and disbursements of counsel), reasonably incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any Governmental Authority, commenced or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission (whether or not a party), to the extent that any such expense is not paid under (i) or (ii) above,

 

*provided*, *however*, that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out of any untrue statement or omission or alleged untrue statement or omission made solely in reliance upon and in conformity with the Agent Information (as defined below).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Agent Indemnification</u>. The Agent agrees to indemnify
and hold harmless the Company and its directors and each officer of the Company who signed the Registration Statement, and each person,
if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act against any
and all loss, liability, claim, damage and expense described in the indemnity contained in <u>Section 10(a)</u>, as incurred, but only
with respect to untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement (or any
amendments thereto), the Prospectus (or any amendment or supplement thereto) or any Issuer Free Writing Prospectus (or any amendment
or supplement thereto) in reliance upon and in conformity with information relating to the Agent and furnished to the Company in writing
by the Agent expressly for use therein. The Company hereby acknowledges that the only information that the Agent has furnished to the
Company expressly for use in the Registration Statement, the Prospectus, any Prospectus Supplement or any Issuer Free Writing Prospectus
(or any amendment or supplement thereto) are the statements set forth in the first sentence of the fifth paragraph and the eighth and
tenth paragraphs under the caption "Plan of Distribution" in the Prospectus (the "  **<u>Agent Information</u>** ").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Procedure</u>. Any party that proposes to assert the right
to be indemnified under this <u>Section 10</u> will, promptly after receipt of notice of commencement of any action against such party
in respect of which a claim is to be made against an indemnifying party or parties under this <u>Section 10</u>, notify each such indemnifying
party of the commencement of such action, enclosing a copy of all papers served, but the omission so to notify such indemnifying party
will not relieve the indemnifying party from (i) any liability that it might have to any indemnified party otherwise than under
this <u>Section 10</u> and (ii) any liability that it may have to any indemnified party under the foregoing provision of this <u>Section 10</u> unless, and only to the extent that, such omission results in the forfeiture of substantive rights or defenses by the indemnifying
party. If any such action is brought against any indemnified party and it notifies the indemnifying party of its commencement, the indemnifying
party will be entitled to participate in and, to the extent that it elects by delivering written notice to the indemnified party promptly
after receiving notice of the commencement of the action from the indemnified party, jointly with any other indemnifying party similarly
notified, to assume the defense of the action, with counsel reasonably satisfactory to the indemnified party, and after notice from the
indemnifying party to the indemnified party of its election to assume the defense, the indemnifying party will not be liable to the indemnified
party for any other legal expenses except as provided below and except for the reasonable and documented costs of investigation subsequently
incurred by the indemnified party in connection with the defense. The indemnified party will have the right to employ its own counsel
in any such action, but the fees, expenses and other charges of such counsel will be at the expense of such indemnified party unless
(1) the employment of counsel by the indemnified party has been authorized in writing by the indemnifying party, (2) the indemnified
party has reasonably concluded (based on advice of counsel) that there may be legal defenses available to it or other indemnified parties
that are different from or in addition to those available to the indemnifying party, (3) a conflict or potential conflict exists
(based on advice of counsel to the indemnified party) between the indemnified party and the indemnifying party (in which case the indemnifying
party will not have the right to direct the defense of such action on behalf of the indemnified party) or (4) the indemnifying party
has not in fact employed counsel to assume the defense of such action or counsel reasonably satisfactory to the indemnified party, in
each case, within a reasonable time after receiving notice of the commencement of the action; in each of which cases the reasonable and
documented out of pocket fees, disbursements and other charges of counsel will be at the expense of the indemnifying party or parties.
It is understood that the indemnifying party or parties shall not, in connection with any proceeding or related proceedings in the same
jurisdiction, be liable for the reasonable and documented out of pocket fees, disbursements and other charges of more than one separate
firm (plus local counsel) admitted to practice in such jurisdiction at any one time for all such indemnified party or parties. All such
documented out of pocket fees, disbursements and other charges will be reimbursed by the indemnifying party promptly after the indemnifying
party or parties receives a written invoice related to fees, disbursements and other charges in reasonable detail. An indemnifying party
will not, in any event, be liable for any settlement of any action or claim effected without its written consent. No indemnifying party
shall, without the prior written consent of each indemnified party, settle or compromise or consent to the entry of any judgment in any
pending or threatened claim, action or proceeding relating to the matters contemplated by this <u>Section 10</u> (whether or not any
indemnified party is a party thereto), unless such settlement, compromise or consent (1) includes an express and unconditional release
of each indemnified party, in form and substance reasonably satisfactory to such indemnified party, from all liability arising out of
such litigation, investigation, proceeding or claim and (2) does not include a statement as to or an admission of fault, culpability
or a failure to act by or on behalf of any indemnified party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Settlement Without Consent if Failure to Reimburse</u> *.* If an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for reasonable fees and expenses
of counsel, for which it is entitled to be reimbursed under this Section 10, such indemnifying party agrees that it shall be liable for
any settlement of the nature contemplated by <u>Section 10(a)(ii)</u> effected without its written consent if (1) such settlement
is entered into more than 45 days after receipt by such indemnifying party of the aforesaid request, (2) such indemnifying party
shall have received notice of the terms of such settlement at least 30 days prior to such settlement being entered into and (3) such
indemnifying party shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Contribution</u>. In order to provide for just and equitable
contribution in circumstances in which the indemnification provided for in the foregoing paragraphs of this <u>Section 10</u> is applicable
in accordance with its terms but for any reason is held to be unavailable or insufficient from the Company or the Agent, the Company
and the Agent will contribute to the total losses, claims, liabilities, expenses and damages (including any investigative, legal and
other expenses reasonably incurred in connection with, and any amount paid in settlement of, any action, suit or proceeding or any claim
asserted) to which the Company and the Agent may be subject in such proportion as shall be appropriate to reflect the relative benefits
received by the Company on the one hand and the Agent on the other hand. The relative benefits received by the Company on the one hand
and the Agent on the other hand shall be deemed to be in the same proportion as the total net proceeds from the sale of the Placement
Shares (before deducting expenses) received by the Company bear to the total compensation received by the Agent (before deducting expenses)
from the sale of Placement Shares on behalf of the Company. If, but only if, the allocation provided by the foregoing sentence is not
permitted by applicable law, the allocation of contribution shall be made in such proportion as is appropriate to reflect not only the
relative benefits referred to in the foregoing sentence but also the relative fault of the Company, on the one hand, and the Agent, on
the other hand, with respect to the statements or omission that resulted in such loss, claim, liability, expense or damage, or action
in respect thereof, as well as any other relevant equitable considerations with respect to such offering. Such relative fault shall be
determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or omission or alleged
omission to state a material fact relates to information supplied by the Company or the Agent, the intent of the parties and their relative
knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and the Agent agree that
it would not be just and equitable if contributions pursuant to this <u>Section 10(e)</u> were to be determined by pro rata allocation
or by any other method of allocation that does not take into account the equitable considerations referred to herein. The amount paid
or payable by an indemnified party as a result of the loss, claim, liability, expense, or damage, or action in respect thereof, referred
to above in this <u>Section 10(e)</u> shall be deemed to include, for the purpose of this <u>Section 10(e)</u>, any legal or other expenses
reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim to the extent consistent
with <u>Section 10(c)</u> hereof. Notwithstanding the foregoing provisions of this <u>Section 10(e)</u>, the Agent shall not be required
to contribute any amount in excess of the commissions received by it under this Agreement and no person found guilty of fraudulent misrepresentation
(within the meaning of <u>Section 11(f)</u> of the Securities Act) will be entitled to contribution from any person who was not guilty
of such fraudulent misrepresentation. For purposes of this <u>Section 10(e)</u>, any person who controls a party to this Agreement within
the meaning of the Securities Act, any affiliates of the Agent and any officers, directors, partners, employees or agents of the Agent
or any of its affiliates, will have the same rights to contribution as that party, and each director of the Company and each officer
of the Company who signed the Registration Statement will have the same rights to contribution as the Company, subject in each case to
the provisions hereof. Any party entitled to contribution, promptly after receipt of notice of commencement of any action against such
party in respect of which a claim for contribution may be made under this <u>Section 10(e)</u>, will notify any such party or parties
from whom contribution may be sought, but the omission to so notify will not relieve that party or parties from whom contribution may
be sought from any other obligation it or they may have under this <u>Section 10(e)</u> except to the extent that the failure to so notify
such other party materially prejudiced the substantive rights or defenses of the party from whom contribution is sought. Except for a
settlement entered into pursuant to the last sentence of <u>Section 10(c)</u> hereof, no party will be liable for contribution with respect
to any action or claim settled without its written consent if such consent is required pursuant to <u>Section 10(c)</u> hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. <u>Representations and Agreements to Survive Delivery</u>. The indemnity and contribution agreements contained
in <u>Section 10</u> of this Agreement and all representations and warranties of the Company herein or in certificates delivered pursuant
hereto shall survive, as of their respective dates, regardless of (i) any investigation made by or on behalf of the Agent, any controlling
persons, or the Company (or any of their respective officers, directors, employees or controlling persons), (ii) delivery and acceptance
of the Placement Shares and payment therefor or (iii) any termination of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. <u>Termination</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Agent may terminate this Agreement, by notice to the
Company, as hereinafter specified at any time (1) if there has been, since the time of execution of this Agreement or since the
date as of which information is given in the Prospectus, any change, or any development or event involving a prospective change, in the
condition, financial or otherwise, or in the business, properties, earnings, results of operations or prospects of the Company and its
Subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business, which individually or in the aggregate,
in the sole judgment of the Agent is material and adverse and makes it impractical or inadvisable to market the Placement Shares or to
enforce contracts for the sale of the Placement Shares, (2) if there has occurred any material adverse change in the financial markets
in the United States or the international financial markets, any outbreak of hostilities or escalation thereof or other calamity or crisis
or any change or development involving a prospective change in national or international political, financial or economic conditions,
in each case the effect of which is such as to make it, in the judgment of the Agent, impracticable or inadvisable to market the Placement
Shares or to enforce contracts for the sale of the Placement Shares, (3) if trading in the Ordinary Shares has been suspended or
limited by the Commission or the Exchange, or if trading generally on the Exchange has been suspended or limited, or minimum prices for
trading have been fixed on the Exchange, (4) if any suspension of trading of any securities of the Company on any exchange or in the
over-the-counter market shall have occurred and be continuing, (5) if a major disruption of securities settlements or clearance services
in the United States shall have occurred and be continuing, or (6) if a banking moratorium has been declared by either U.S. Federal
or New York authorities. Any such termination shall be without liability of any party to any other party except that the provisions of <u>Section 7(h)</u> (Notice of Other Sales), <u>Section 8</u> (Payment of Expenses), <u>Section 10</u> (Indemnification and Contribution), <u>Section 11</u> (Representations and Agreements to Survive Delivery), <u>Section 17</u> (Governing Law and Time; Waiver of Jury Trial), <u>Section 18</u> (Consent to Jurisdiction), <u>Section 19</u> (Recognition of the U.S. Special Resolution Regimes), <u>Section 20</u> (Appointment of Agent for Service) and <u>Section 21</u> (Judgment Currency) hereof shall remain in full force and effect notwithstanding
such termination. If the Agent elects to terminate this Agreement as provided in this <u>Section 12(a)</u>, the Agent shall provide the
required notice as specified in <u>Section 13</u> (Notices).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Company shall have the right, by giving ten (10) days'
notice as hereinafter specified to terminate this Agreement in its sole discretion at any time after the date of this Agreement. Any
such termination shall be without liability of any party to any other party except that the provisions of <u>Section 7(h)</u>, <u>Section 8</u>, <u>Section 10</u>, <u>Section 11</u>, <u>Section 17</u>, <u>Section 18</u>, <u>Section 19</u>, <u>Section 20</u> and <u>Section 21</u> hereof shall remain in full force and effect notwithstanding such termination.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Agent shall have the right, by giving ten (10) days'
notice as hereinafter specified to terminate this Agreement in its sole discretion at any time after the date of this Agreement. Any
such termination shall be without liability of any party to any other party except that the provisions of <u>Section 7(h)</u>, <u>Section 8</u>, <u>Section 10</u>, <u>Section 11</u>, <u>Section 17</u>, <u>Section 18</u>, <u>Section 19</u>, <u>Section 20</u> and <u>Section 21</u> hereof shall remain in full force and effect notwithstanding such termination.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) This Agreement shall remain in full force and effect unless
terminated pursuant to Sections 12(a), (b), or (c) above or otherwise by mutual agreement of the parties; provided, however, that any
such termination by mutual agreement shall in all cases be deemed to provide that <u>Section 7(h)</u>, <u>Section 8</u>, <u>Section 10</u>, <u>Section 11</u>, <u>Section 17</u> and <u>Section 18</u>, shall remain in full force and effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Any termination of this Agreement shall be effective on the
date specified in such notice of termination; provided, however, that such termination shall not be effective until the close of business
on the date of receipt of such notice by the Agent or the Company, as the case may be. If such termination shall occur prior to the Settlement
Date for any sale of Placement Shares, such Placement Shares shall settle in accordance with the provisions of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13. <u>Notices</u>. All notices or other communications required or permitted to be given by any party to
any other party pursuant to the terms of this Agreement shall be in writing, unless otherwise specified, and if sent to the Agent, shall
be delivered to:

Cantor Fitzgerald & Co.

110 East 59th Street

New York, New York 10022

Attention: Capital Markets

Email: CFCEO@cantor.com

and:

Cantor Fitzgerald & Co.

110 East 59th Street

New York, New York 10022

Attention: General Counsel

Email: legal-IBD@cantor.com

with a copy to:

DLA Piper LLP (US)

1251 Avenue of the Americas

New York, New York 10020

Attention: Stephen P. Alicanti

Email: stephen.alicanti@us.dlapiper.com

and if to the Company, shall be delivered to:

Brera Holdings PLC<br> Connaught House, 5th Floor, One Burlington Road

Dublin 4, D04 C5Y6, Ireland

Email: dan@breraholdings.com

with a copy to:

Lowenstein Sandler LLP<br> 1251 Avenue of the Americas<br> New York, New York 10020<br> Attention: Daniel Forman

Email: dforman@lowenstein.com

Each party to this Agreement may change such address for notices by sending to the parties to this Agreement written notice of a new address for such purpose. Each such notice or other communication shall be deemed given (i) when delivered personally or by verifiable facsimile transmission (with an original to follow) on or before 4:30 p.m., New York City time, on a Business Day or, if such day is not a Business Day, on the next succeeding Business Day, (ii) by Electronic Notice, as set forth below, (iii) on the next Business Day after timely delivery to a nationally-recognized overnight courier and (iv) on the Business Day actually received if deposited in the U.S. mail (certified or registered mail, return receipt requested, postage prepaid). For purposes of this Agreement, "**<u>Business Day</u>**" shall mean any day on which the Exchange and commercial banks in the City of New York are open for business.

An electronic communication ("**<u>Electronic Notice</u>**") shall be deemed written notice for purposes of this <u>Section 13</u> if sent to the electronic mail address specified by the receiving party under separate cover. Electronic Notice shall be deemed received at the time the party sending Electronic Notice receives verification of receipt by the receiving party. Any party receiving Electronic Notice may request and shall be entitled to receive the notice on paper, in a nonelectronic form ("**<u>Nonelectronic Notic</u>e**") which shall be sent to the requesting party within ten (10) days of receipt of the written request for Nonelectronic Notice.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14. <u>Successors and Assigns</u>. This Agreement shall inure to the benefit of and be binding upon the Company
and the Agent and their respective successors and the parties referred to in Section 10 hereof. References to any of the parties contained
in this Agreement shall be deemed to include the successors and permitted assigns of such party. Nothing in this Agreement, express or
implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assigns any rights,
remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. Neither party
may assign its rights or obligations under this Agreement without the prior written consent of the other party; *provided*, *however*,
that the Agent may assign its rights and obligations hereunder to an affiliate thereof without obtaining the Company's consent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15. <u>Adjustments for Stock Splits</u>. The parties acknowledge and agree that all share-related numbers
contained in this Agreement shall be adjusted to take into account any stock split, stock dividend or similar event effected with respect
to the Ordinary Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16. <u>Entire Agreement; Amendment; Severability; Waiver</u>. This Agreement (including all schedules and
exhibits attached hereto, and Placement Notices issued pursuant hereto, any contemporaneous side letters and any prior engagement letters
between the Company and the Agent) constitutes the entire agreement and supersedes all other prior and contemporaneous agreements and
undertakings, both written and oral, among the parties hereto with regard to the subject matter hereof. Neither this Agreement nor any
term hereof may be amended except pursuant to a written instrument executed by the Company and the Agent. In the event that any one or
more of the provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable as
written by a court of competent jurisdiction, then such provision shall be given full force and effect to the fullest possible extent
that it is valid, legal and enforceable, and the remainder of the terms and provisions herein shall be construed as if such invalid, illegal
or unenforceable term or provision was not contained herein, but only to the extent that giving effect to such provision and the remainder
of the terms and provisions hereof shall be in accordance with the intent of the parties as reflected in this Agreement. No implied waiver
by a party shall arise in the absence of a waiver in writing signed by such party. No failure or delay in exercising any right, power,
or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or further
exercise thereof or the exercise of any right, power, or privilege hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17.  **<u>GOVERNING LAW AND TIME; WAIVER OF JURY TRIAL</u>. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAWS. SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. EACH PARTY HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.  **<u>CONSENT TO JURISDICTION</u>. EACH PARTY HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH ANY TRANSACTION CONTEMPLATED HEREBY, AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT, THAT SUCH SUIT, ACTION OR PROCEEDING IS BROUGHT IN AN INCONVENIENT FORUM OR THAT THE VENUE OF SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER. EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF (CERTIFIED OR REGISTERED MAIL, RETURN RECEIPT REQUESTED) TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. TO THE EXTENT THAT THE COMPANY HAS OR HEREAFTER MAY ACQUIRE ANY IMMUNITY (ON THE GROUNDS OF SOVEREIGNTY OR OTHERWISE) FROM THE JURISDICTION OF ANY COURT OR FROM ANY LEGAL PROCESS WITH RESPECT TO ITSELF OR ITS PROPERTY, THE COMPANY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, SUCH IMMUNITY IN RESPECT OF ANY SUCH SUIT, ACTION OR PROCEEDING.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19. <u>Recognition of the U.S. Special Resolution Regimes</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) In the event that the Agent that is a Covered Entity becomes
subject to a proceeding under a U.S. Special Resolution Regime, the transfer from the Agent of this Agreement, and any interest and obligation
in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution
Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United
States.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) In the event that the Agent that is a Covered Entity or a
BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this
Agreement that may be exercised against the Agent are permitted to be exercised to no greater extent than such Default Rights could be
exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the
United States.

As used in this <u>Section 19</u>, "**<u>BHC Act Affiliate</u>**" has the meaning assigned to the term "affiliate" in, and shall be interpreted in accordance with, 12 U.S.C. § 1841(k); "**<u>Covered Entity</u>**" means any of the following: (i) a "covered entity" as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b), (ii) a "covered bank" as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b) or (iii) a "covered FSI" as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b); "**<u>Default Right</u>**" has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable; and "**<u>U.S. Special Resolution Regime</u>**" means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20. <u>Appointment of Agent for Service</u>. The Company hereby irrevocably appoints Lowenstein Sandler LLP,
1251 Avenue of the Americas, New York, New York 10020 as its agent for service of process in any suit, action or proceeding described
in <u>Section 18</u> and agrees that service of process in any such suit, action or proceeding may be made upon it at the office of such
agent. The Company waives, to the fullest extent permitted by law, any other requirements of or objections to personal jurisdiction with
respect thereto. The Company represents and warrants that such agent has agreed to act as the Company's agent for service of process,
and the Company agrees to take any and all action, including the filing of any and all documents and instruments, that may be necessary
to continue such appointment in full force and effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21. <u>Judgment Currency</u>. If for the purposes of obtaining
judgment in any court it is necessary to convert a sum due hereunder into any currency other than United States dollars, the parties
hereto agree, to the fullest extent permitted by law, that the rate of exchange used shall be the rate at which in accordance with normal
banking procedures the Agent could purchase United States dollars with such other currency in The City of New York on the Business Day
preceding that on which final judgment is given. The obligation of the Company with respect to any sum due from it to the Agent or any
person controlling the Agent shall, notwithstanding any judgment in a currency other than United States dollars, not be discharged until
the first Business Day following receipt by the Agent or any person controlling the Agent of any sum in such other currency, and only
to the extent that the Agent or controlling person may in accordance with normal banking procedures purchase United States dollars with
such other currency. If the United States dollars so purchased are less than the sum originally due to the Agent or controlling person
hereunder, the Company agrees as a separate obligation and notwithstanding any such judgment, to indemnify the Agent or controlling person
against such loss. If the United States dollars so purchased are greater than the sum originally due to the Agent or controlling person
hereunder, the Agent or controlling person agrees to pay to the Company an amount equal to the excess of the dollars so purchased over
the sum originally due to the Agent or controlling person hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22. <u>Counterparts</u>. This Agreement may be executed in two or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. Delivery of an executed Agreement by one party
to the other may be made by facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000,
Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other
transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective
for all purposes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23. <u>Construction</u>. The section and exhibit headings herein are for convenience only and shall not
affect the construction hereof. References herein to any law, statute, ordinance, code, regulation, rule or other requirement of any Governmental
Authority shall be deemed to refer to such law, statute, ordinance, code, regulation, rule or other requirement of any Governmental Authority
as amended, reenacted, supplemented or superseded in whole or in part and in effect from time to time and also to all rules and regulations
promulgated thereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24. <u>Permitted Free Writing Prospectuses</u>. The Company represents, warrants and agrees that, unless it
obtains the prior written consent of the Agent, and the Agent represents, warrants and agrees that, unless it obtains the prior written
consent of the Company, it has not made and will not make any offer relating to the Placement Shares that would constitute an Issuer Free
Writing Prospectus, or that would otherwise constitute a "free writing prospectus," as defined in Rule 405, required
to be filed with the Commission. Any such free writing prospectus consented to by the Agent or by the Company, as the case may be, is
hereinafter referred to as a "Permitted Free Writing Prospectus." The Company represents and warrants that it has treated
and agrees that it will treat each Permitted Free Writing Prospectus as an "issuer free writing prospectus," as defined in
Rule 433, and has complied and will comply with the requirements of Rule 433 applicable to any Permitted Free Writing Prospectus,
including timely filing with the Commission where required, legending and record keeping. For the purposes of clarity, the parties hereto
agree that all free writing prospectuses, if any, listed in <u>Exhibit 21</u> hereto are Permitted Free Writing Prospectuses.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25. <u>Absence of Fiduciary Relationship</u>. The Company acknowledges and agrees that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the Agent is acting solely as agent in connection with the public offering of the Placement Shares and
in connection with each transaction contemplated by this Agreement and the process leading to such transactions, and no fiduciary or advisory
relationship between the Company or any of its respective affiliates, shareholders (or other equity holders), creditors or employees or
any other party, on the one hand, and the Agent, on the other hand, has been or will be created in respect of any of the transactions
contemplated by this Agreement, irrespective of whether or not the Agent has advised or is advising the Company on other matters, and
the Agent has no obligation to the Company with respect to the transactions contemplated by this Agreement except the obligations expressly
set forth in this Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) it is capable of evaluating and understanding, and understands and accepts, the terms, risks and conditions
of the transactions contemplated by this Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) neither the Agent nor its affiliates have provided any legal, accounting, regulatory or tax advice with
respect to the transactions contemplated by this Agreement and it has consulted its own legal, accounting, regulatory and tax advisors
to the extent it has deemed appropriate;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) it is aware that the Agent and its affiliates are engaged in a broad range of transactions which may involve
interests that differ from those of the Company and the Agent and its affiliates have no obligation to disclose such interests and transactions
to the Company by virtue of any fiduciary, advisory or agency relationship or otherwise; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) it waives, to the fullest extent permitted by law, any claims it may have against the Agent or its affiliates
for breach of fiduciary duty or alleged breach of fiduciary duty in connection with the sale of Placement Shares under this Agreement
and agrees that the Agent and its affiliates shall not have any liability (whether direct or indirect, in contract, tort or otherwise)
to it in respect of such a fiduciary duty claim or to any person asserting a fiduciary duty claim on its behalf or in right of the Company,
including shareholders, employees and creditors of the Company , other than in respect of the Agents' obligations under this Agreement
to keep information provided by the Company to the Agents and their advisors confidential to the extent not otherwise publicly available.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;26. Reporting Relating to Placement of Placement Shares. Upon written request by the Company, the Agent will
use commercially reasonable efforts to deliver to the Company, for each interim and annual period during which Placement Shares are sold
through the Agent or distributed pursuant to this Agreement, such aggregate Sales Data and other information reasonably requested by the
Company to enable the Company to meet its reporting requirements under the Securities Act, the Exchange Act and any applicable requirements
of the Nasdaq. Unless applicable securities laws or any applicable requirements of the Nasdaq otherwise require, the Company and Agent
agree that the Agent's report referred to in this Section 26 shall state the number and average price of Placement Shares issued
on all Settlement Dates occurring during the interim or annual period, as applicable, and the aggregate gross and the aggregate net proceeds
raised and the aggregate commission paid or payable, during the interim or annual period, as applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27. <u>Definitions</u>. As used in this Agreement, the following terms have the respective meanings set forth
below:

"**<u>Applicable Time</u>**" means (i) each Representation Date, (ii) the time of each sale of any Placement Shares pursuant to this Agreement and (iii) each Settlement Date.

"**<u>Governmental Authority</u>**" means (i) any federal, provincial, state, local, municipal, national or international government or governmental authority, regulatory or administrative agency, governmental commission, department, board, bureau, agency or instrumentality, court, tribunal, arbitrator or arbitral body (public or private); (ii) any self-regulatory organization; or (iii) any political subdivision of any of the foregoing.

"**<u>Issuer Free Writing Prospectus</u>**" means any "issuer free writing prospectus," as defined in Rule 433, relating to the Placement Shares that (1) is required to be filed with the Commission by the Company, (2) is a "road show" that is a "written communication" within the meaning of Rule 433(d)(8)(i) whether or not required to be filed with the Commission, or (3) is exempt from filing pursuant to Rule 433(d)(5)(i) because it contains a description of the Placement Shares or of the offering that does not reflect the final terms, in each case in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company's records pursuant to Rule 433(g) under the Securities Act Regulations.

"**<u>Rule 164</u>**," "**<u>Rule 172</u>**," "**<u>Rule 405</u>**," "**<u>Rule 415</u>**," "**<u>Rule 424</u>**," "**<u>Rule 424(b)</u>**," "**<u>Rule 430B</u>**," and "**<u>Rule 433</u>**" refer to such rules under the Securities Act Regulations.

All references in this Agreement to financial statements and schedules and other information that is "contained," "included" or "stated" in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed to mean and include all such financial statements and schedules and other information that is incorporated by reference into the Registration Statement or the Prospectus, as the case may be.

All references in this Agreement to the Registration Statement, the Prospectus or any amendment or supplement to any of the foregoing shall be deemed to include the copy filed with the Commission pursuant to EDGAR; all references in this Agreement to any Issuer Free Writing Prospectus (other than any Issuer Free Writing Prospectuses that, pursuant to Rule 433, are not required to be filed with the Commission) shall be deemed to include the copy thereof filed with the Commission pursuant to EDGAR; and all references in this Agreement to "supplements" to the Prospectus shall include, without limitation, any supplements, "wrappers" or similar materials prepared in connection with any offering, sale or private placement of any Placement Shares by the Agent outside of the United States.

[***Signature Page Follows***]

If the foregoing correctly sets forth the understanding between the Company and the Agent, please so indicate in the space provided below for that purpose, whereupon this Agreement shall constitute a binding agreement between the Company and the Agent.

---

| | | |
|:---|:---|:---|
| Very truly yours, | Very truly yours, | Very truly yours, |
| **Brera Holdings PLC** | **Brera Holdings PLC** | **Brera Holdings PLC** |
| By: | /s/ Marco Santori | /s/ Marco Santori |
|  | Name: | Marco Santori |
|  | Title: | Chief Executive Officer |

---

---

| | | |
|:---|:---|:---|
| ACCEPTED as of the date first-above written: | ACCEPTED as of the date first-above written: | ACCEPTED as of the date first-above written: |
| **CANTOR FITZGERALD & CO.** | **CANTOR FITZGERALD & CO.** | **CANTOR FITZGERALD & CO.** |
| By: | /s/ Sameer Vasudev | /s/ Sameer Vasudev |
|  | Name: | Sameer Vasudev |
|  | Title: | Managing Director  |

---

*[Signature Page to Sales Agreement]*

**SCHEDULE 1**

**Form of Placement Notice**

From: Brera Holdings PLC

To: Cantor Fitzgerald & Co.<br> 110 East 59th Street<br> New York, NY 10022<br> Attention: Sameer Vasudev

Subject: Placement Notice

Date: [●], 20[●]

Ladies and Gentlemen:

Pursuant to the terms and subject to the conditions contained in the Sales Agreement by and among Brera Holdings PLC, a private company limited by shares incorporated under the laws of Ireland (the "**<u>Company</u>**"), Cantor Fitzgerald & Co., dated November 18, 2025, the Company hereby requests that Cantor Fitzgerald & Co. sell up to [●] of the Company's Class B ordinary shares, $0.05 nominal value per share, at a minimum market price of $[●] per share, during the time period beginning [month, day, time] and ending [month, day, time].

**SCHEDULE 2**

**Compensation**

The Company shall pay to the Agent in cash, upon each sale of Placement Shares pursuant to this Agreement, an amount equal to 3.0% of the aggregate gross proceeds from each sale of Placement Shares.

**SCHEDULE 3**

**Notice Parties**

<u>The Company</u>

Marco Santori (marco@solmate.com)

<u>Cantor Fitzgerald & Co.</u>

Sameer Vasudev (svasudev@cantor.com)

With copies to:

CFCEO@cantor.com

**SCHEDULE 4**

**Subsidiaries**

Incorporated by reference to Exhibit 8.1 of the Company's most recently filed Annual Report on Form 20-F.

**Form of Representation Date Certificate Pursuant to Section 7(l)**

The undersigned, the duly qualified and elected [●], of Brera Holdings PLC, a private company limited by shares incorporated under the laws of Ireland (the "<u>Company</u>"), does hereby certify in such capacity and on behalf of the Company, pursuant to <u>Section 7(l)</u> of the Sales Agreement, dated November 18, 2025 (the "<u>Sales Agreement</u>"), by and between the Company and Cantor Fitzgerald & Co., that to the best of the knowledge of the undersigned:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The representations and warranties of the Company in <u>Section 6</u> of the Sales Agreement are true and correct in all material respects on and as of the date hereof with the same force and effect as if expressly made on and as of the date hereof, except for those representations and warranties that speak solely as of a specific date and which were true and correct as of such date; *provided*, *however*, that such representations and warranties shall be qualified by the disclosure included in or incorporated by reference into the Registration Statement and Prospectus; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) The Company has complied in all material respects with all agreements and satisfied all conditions on its part required to be performed or satisfied pursuant to the Sales Agreement at or prior to the date hereof.

Capitalized terms used herein without definition shall have the meanings given to such terms in the Sales Agreement.

---

| |
|:---|
| BRERA HOLDINGS PLC |
| By: |
| Name: |
| Title: |

---

Date: [●]

**<u>Exhibit 21</u>**

**Permitted Free Writing Prospectus**

None.

## Exhibit 5.1

**Exhibit 5.1**

18 November 2025

To:

Brera Holdings PLC

Connaught House

One Burlington Road

Dublin 4

D04 C5Y6

**Re: Brera Holdings Public Limited Company – CRO No. 721923 (the Company)**

Dear Sirs,

1. Introduction

We are instructed as Irish solicitors by the Board of Directors of the Company to provide certain Irish Law legal advice in connection with a registration statement on Form F-3 (File No. 333-276870) with an effective date of February 13, 2024 (the "**Registration Statement**"), including a Prospectus Supplement (the "**ATM Prospectus**") dated November 18, 2025 related to an at-the-market offering of up to $98,500,000 of Class B Ordinary Shares (such Class B Ordinary Shares, the "**ATM Shares**") filed with the U.S. Securities and Exchange Commission, relating to the shelf registration under the U.S. Securities Act of 1933, as amended (the "**Transaction**").

This legal opinion is issued pursuant to the Legal Matters section of the Registration Statement and the Legal Matters section of the ATM Prospectus (the "**Legal Opinion**").

In providing this Legal Opinion, we put you on express notice that we have reviewed only the documents listed in listed in Part 1 of Schedule 1 (each a "**Document**" and collectively, the "**Documents**") and undertaken only the searches and enquiries in relation to the Company described in Part 2 of Schedule 1 (the Searches). We have reviewed no other documents and have undertaken no other searches or enquiries.

2. Opinions

Based only on our review of the Documents and upon the assumptions set out in Schedule 2, and subject to all applicable bankruptcy, insolvency, liquidation, examinership, re-organisation, moratorium and other laws relating to the enforcement of creditors' rights generally and the qualifications set out in Schedule 3, we are of the following opinions as at today's date:

1) The ATM Shares have been duly authorized for issuance, and when the ATM Shares are issued and paid for in accordance with the Sales Agreement (as defined below) and the ATM Prospectus and registered in the register of members of the Company, they will be validly issued, fully paid and non-assessable (which term, when used herein, means that the holders of the ATM Shares are not liable, solely by virtue of holding such ATM Shares, for additional assessments or calls on such ATM Shares by the Company or its creditors) shares in the capital of the Company. The ATM Shares are free of statutory preemptive rights, rights of first refusal and restrictions upon voting or transfer contained in the Charter (as defined below) or Constitution of the Company or in any agreement to which the Company is a party that is attached as an exhibit to the Registration Statement.

3 Reliance

This Legal Opinion is solely for your benefit, solely for the purpose of the ATM Prospectus and may be relied on only by you. It may not be relied on for any other purpose or disclosed to, used by or circulated to any other person without our prior written consent in each instance which consent shall be at our absolute discretion.

We consent to the filing of this Legal Opinion as an exhibit to the Report on Form 6-K filed by the Company on the date hereof and which is incorporated by reference into the ATM Prospectus and to the references to our firm under the captions "Legal Matters" and "Enforcement of Civil Liabilities" in the ATM Prospectus forming a part of the Registration Statement. In giving such consent, we do not hereby admit that we are experts within the meaning of Section 11 of the Securities Act or that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the Rules and Regulations of the Commission promulgated thereunder. We accept no liability to any recipient to which this Legal Opinion is disclosed in breach of this part 3.

We have taken instructions solely from the Company for the purpose of preparing the Legal Opinion.

This Legal Opinion is given by Clark Hill Solicitors LLP and no partner, member, or employee assumes any personal responsibility for it or shall owe any duty of care in respect of it.

4 Scope

The opinions in this Legal Opinion are strictly limited to the matters stated in part 2 and do not extend to any other matters.

We express no opinion on any taxation matters whether connected with the Transaction or otherwise.

We express no opinion on matters of fact. We have not been responsible for investigating or verifying the accuracy of the facts (including statements of foreign law), or the reasonableness of any statement of opinion or intention, contained in or relevant to any document referred to in this Legal Opinion, or that no material facts have been omitted from such documents.

This Legal Opinion and any non-contractual obligation arising out of it is given only in relation to Irish law as applied by the Irish courts as at the date of this Legal Opinion. By giving this Legal Opinion, we do not assume any obligation to notify you of future changes in law which may affect the opinions expressed in this Legal Opinion, or otherwise to update this letter in any respect.

We express no opinion on and have taken no account of the laws of any jurisdiction other than Ireland.

Yours faithfully

---

| |
|:---|
| /s/ Clark Hill Solicitors LLP |
| **Clark Hill Solicitors LLP** |

---

**SCHEDULE 1**

**PART 1**

Documents

The Registration Statement,

The ATM Prospectus,

The Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. dated November 18, 2025 (the "**Sales Agreement**"),

A secretary and officer's certificate of the Company dated November 18, 2025 (the "**Corporate Certificate**"),

A written resolution of the board of directors of the Company dated November 17, 2025 (the "**Board Resolution**"),

Letter of Status from the Companies Registration Office dated November 17, 2025,

Companies Registration Office Printout dated November 18, 2025,

The certificate of incorporation of the Company (the "**Charter**"),

The Constitution of the Company,

The documents listed above are referred to as the "**Documents**" and individually a "**Document**".

**PART 2**

Searches

Searches made against Company by independent law searchers on our behalf on November 18, 2025:

&nbsp;&nbsp;&nbsp;&nbsp;(a) on the file of the Company maintained by the registrar of companies in the Companies Registration Office;

&nbsp;&nbsp;&nbsp;&nbsp;(b) in the Judgments Office of the High Court for unsatisfied judgments, orders, decrees and the like;

&nbsp;&nbsp;&nbsp;&nbsp;(c) in the Central Office of the High Court for any petitions for winding up filed in respect of the Company; and

&nbsp;&nbsp;&nbsp;&nbsp;(d) in the Central Office of the High Court for any proceedings filed against the Company.

**SCHEDULE 2**

Assumptions

The opinions in part 2 of this Legal Opinion are made based on the following assumptions which we have made without independent verification:

1. That the Documents are complete, properly under seal as and where required by law and the Company constitution, authentic and up-to-date and that all copy documents are complete and accurate copies of the originals without any amendment or modification, that unsigned or unexecuted documents reviewed by us will be duly executed in the same form as that reviewed by us, all signatures and seals on the Documents are genuine, that any natural person who has signed a document has capacity to do so and is the person authorised in the Board Resolution, each party to the Documents has the capacity, power and authority to execute the Documents to which it is a party and to exercise its rights and perform its obligations under the Documents to which it is a party and in each case the Document has been authorize, executed and delivered by and to the said parties and that no Transaction is subject to an escrow, equivalent or like arrangement.

2. That the ATM Shares will be issued and sold strictly in the manner and in the amounts provided for in the Documents.

3. The Documents constitute valid, legally binding and enforceable obligations of each of the parties under all applicable laws including where executed by electronic signature (other than Ireland)and to the extent that laws or regulations of any other jurisdiction may be relevant to parties and/or the Transaction such laws do not prohibit, and are not inconsistent with, the entry into and performance of any of the obligations created, rights given or transactions contemplated as part of the Documents.

4. That there is no provision of the laws of any jurisdiction (other than Ireland) that would have a bearing on any of the matters opined on in this Legal Opinion, including the execution of the Documents.

5. That each of the statements made in the Corporate Certificate and each of the documents attached to the Corporate Certificate is true, accurate and complete as of the date of this Legal Opinion.

6. That the resolutions of the board of directors of the Company in the Board Resolution are accurately and completely recorded, have not been amended or rescinded and are in full force and effect.

7. That the provisions of the Documents do not breach and are not prohibited by or inconsistent with any other agreement or instrument binding on the Company, the directors of the Company acted in good faith, entered into the Documents for bona fide commercial reasons, on arm's length terms and that it is in the interests of and will commercially benefit the Company to enter into the Documents and where a director has a personal interest, this has been declared to the directors of the Company.

8. The Company is able to pay its debts (within the meaning of section 570 of the Companies Act 2014) at the time of entering into the Documents and will not become unable to pay its debts as a result of doing so. The Company has not passed any resolution for its winding-up or dissolution and no proceedings have been commenced or steps taken for its winding-up or for the appointment of an administrator, a liquidator, or receiver in relation to the Company or any of its assets or revenue. No analogous procedure or step has been taken in any jurisdiction in relation to the Company.

9. That any and all authorisation, consent or approval from any public, administrative or governmental body required by the Company in any jurisdiction in relation to the transactions contemplated by the Documents has been obtained and the Company has complied, and will continue to comply, with any conditions attaching to such authorisations, consents or approvals.

10. That all ATM Shares to be issued and sold pursuant to the Transaction will have been issued and sold in compliance with all laws (other than Irish law), including applicable federal and state securities laws of the United States of America in the manner provided for in the Documents.

11. That the Company its servants, employees and agents were not induced by and did not themselves seek to induce any other party by means of, bad faith, fraud, misrepresentation, coercion, duress, undue influence or any similar circumstance the entering into of the Documents, and none of the parties is or will be seeking to achieve any benefit or purpose not apparent from the Documents which might render any of them illegal, void or unenforceable and there are no undisclosed agreements or arrangements in existence which in any way amend, or vary the terms of the Documents or the respective rights and interests of the parties to them that could affect the conclusions in this Legal Opinion.

12. That the representations and warranties by any of the parties to the Documents are and will, when made and/or repeated or when deemed made and/or repeated, in each case, be true, complete and accurate in all material respects.

13. That, the Company is not giving any financial assistance for the purposes of acquiring shares in the Company and for the purposes of section 239 of the Irish Companies Act 2014, the Company is not:

&nbsp;&nbsp;&nbsp;&nbsp;(a) making a loan or quasi-loan;

&nbsp;&nbsp;&nbsp;&nbsp;(b) entering into a credit transaction as creditor; or

&nbsp;&nbsp;&nbsp;&nbsp;(c) entering into a guarantee or providing any security in connection with a loan, quasi-loan or credit transaction made by any other
person,

to or provided for or in connection with a person who is a director of the Company or of its holding company or to or for a person connected with such director.

14. That the information disclosed by the Searches is true, accurate, complete and up to date in all respects. There is no information which should have been disclosed by those Searches or otherwise that has not been disclosed for any reason and there has been no alteration in the status or condition of the Company since the date that those Searches were made and that there is no other fact, matter or document which would, or might, affect this Legal Opinion that was not revealed by the Documents or the Searches made.

15. That the shares in the capital of the Company will not be listed or admitted to trading on any stock exchange or public market other than under the listing arrangements disclosed.

16. Any non-cash asset accepted as consideration by the Company for the issue of ATM Shares has been appropriately valued and section 1029(4) of the Irish Companies Act 2014 does not apply to any such consideration, the value of the consideration accepted by the Company will equate to the nominal value plus the share premium when issued and no person has made a statement to which section 1030(4) of the Irish Companies Act 2014 applies that is, a statement which is false or misleading as to the value of such consideration.

17. The parties have complied (and will continue to comply) with all applicable anti-terrorism, anti-corruption, anti-money laundering and human rights laws and regulations and there is nothing in the Transaction that is inconsistent with all such laws and regulations.

18. That the Irish Takeover Panel Rules, as in force at the date of this Legal Opinion, have been duly complied with in all material respects by all relevant parties, and that no waiver, dispensation, derogation, or determination of the Irish Takeover Panel applies to the matters considered herein, other than as expressly disclosed to us.

19. That the Irish Takeover Panel will exercise its functions and exercise its functions in a lawful, rational and non-arbitrary manner, and will not vary, revoke, reinterpret or otherwise alter its published rules or practice in a way that would materially affect the conclusions expressed in this Legal Opinion.

20. The accuracy and completeness of all factual representations made in the Registration Statement and other documents reviewed by us.

**SCHEDULE 3**

Qualifications

The opinions in part 2 of this Legal Opinion are made subject to the following qualifications:

&nbsp;&nbsp;&nbsp;&nbsp;1. The searches and enquiries listed in Schedule 1 Part 2 of this Legal Opinion are not conclusively capable of revealing whether
or not (i) a winding up order has been made or a resolution passed for the winding up of the Company or (ii) a liquidator, administrator
or other manager has been appointed as notice of these matters may not be filed immediately and, when filed, may not be entered on the
public file immediately (and in addition, that search is not capable of revealing, prior to the making of the relevant order, whether
or not a winding up petition has been presented);

&nbsp;&nbsp;&nbsp;&nbsp;2. Under the laws of Ireland, a person who is not a party to any agreement is unable to enforce it.

&nbsp;&nbsp;&nbsp;&nbsp;3. In order to continue in good standing under the laws of Ireland, the Company is required, inter alia, to pay annual fees to and file
annual returns with the Companies Registration Office.

&nbsp;&nbsp;&nbsp;&nbsp;4. This Legal Opinion is subject to all insolvency, bankruptcy, liquidation, receivership, moratorium, reorganisation or similar laws
affecting the rights of creditors (including secured creditors) generally.

&nbsp;&nbsp;&nbsp;&nbsp;5. This Legal Opinion is based on information available as of the date of signature of this Legal Opinion, and we undertake no obligation
to update the Legal Opinion subsequently.

&nbsp;&nbsp;&nbsp;&nbsp;6. We have made no investigation as to whether or not sanctions may affect the Transaction at the date of
this Legal Opinion. Any obligation or right of a party to a Document who is directly or indirectly subject to sanction imposed or recognized
by Ireland is void.

&nbsp;&nbsp;&nbsp;&nbsp;7. We have made no investigation and express no opinion as to the adequacy of the consideration received
or to be received by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;8. We have prepared this Legal Opinion on a diligent and careful basis. Our liability in respect of any error, omission, misstatement
or negligence in providing this Legal Opinion shall be capped and restricted to the sum of $50,000,000 (fifty million US Dollars) in aggregate.

&nbsp;&nbsp;&nbsp;&nbsp;9. The Irish Takeover Panel has broad statutory powers of interpretation, discretion and intervention under the Irish Takeover Panel
Act 1997 (as amended) and the Irish Takeover Panel Rules. We express no opinion as to how the Irish Takeover Panel may exercise such powers
in practice, or as to the likelihood of the Irish Takeover Panel granting any waiver, dispensation or derogation from the application
of the Irish Takeover Rules.